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Abstract
Non-invasive, transcutaneous low intensity pulsed ultrasound (LIPUS) therapy has shown
clinical efficacy in bone healing for over the past two decades; however, the exact mechanism of
action remains largely unknown. The goal of this work was to find more conclusive evidence as
to how LIPUS works in addition to optimizing the currently used clinical therapy. We developed
and characterized our own highly tunable ultrasound system as well as a hydrogel scaffold system
for tissue mimetics. A series of experiments evaluated the response of our adjustable ultrasound
system to: cells alone; hydrogels alone; cell-hydrogel encapsulation; and cell-hydrogel
encapsulation implantation into a mouse calvarial model.
By characterizing our tunable ultrasound system with a needle hydrophone, we found that
the clinical LIPUS parameter produces a measurable acoustic radiation force previously only
recognized in higher intensity ultrasound modalities. Given that bone responds positively to
physical forces, we have attempted to relate the documented benefit of LIPUS therapy in bone
healing to acoustic radiation forces as a likely candidate for LIPUS efficacy. Through our
adjustable LIPUS system and the development of collagen hydrogel scaffolds, we demonstrated
that varying LIPUS intensity and duty cycle results in the manifestation of varying physical loads.
These loads ultimately lead to the quantifiable deformation of collagen hydrogel scaffolds through
the displacement of fluorescent beacons encapsulated within the hydrogels. By application of
acoustic radiation force, pre-osteoblast cell-encapsulated hydrogels experienced varied osteogenic
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response from the clinical intensity of LIPUS based on their collagen concentration. Also, the
exposure of cell-hydrogel constructs to ultrasound resulted in the varied upregulation of certain
markers indicative of mechanical stress, based on LIPUS intensity and hydrogel collagen
concentration. As fractures are typically immobilized during the fracture healing process, local
bone cells receive limited beneficial physical loading. To this end, we used a mouse calvarial
defect model to encapsulate donor bone marrow stromal cells (BMSCs) within a collagen hydrogel
at the defect site to physically load cells during the fracture healing process in hopes to enhance
the currently used clinical LIPUS therapy.
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1. INTRODUCTION

1.1. Clinical Relevance

Annually, orthopedic surgeons perform approximately 2.2 million bone replacement
procedures worldwide, of which over 500,000 procedures are performed in the United States,
leading to bone being the second most transplanted tissue after blood. 1,2 In the United States
alone, bone replacement procedures result in a cost of nearly $2.5 billion per year on the
healthcare system.3 In healthy individuals bone tissue has the ability to regenerate and repair
non-critical sized defects. 4,5 However, when patients experience critical sized defects or bone
loss due to trauma, tumor resection, developmental deformities, infection, or non -union
fractures, bone cannot heal properly on its own resulting in necessary surgical intervention
with bone replacements/grafts.6–9 With the rising age of the population in the United States,
particularly considering the baby boomer generation cohort of ~65 million began turning 65
years old in 2011, susceptibility to musculoskeletal ailments increases in part due to ageassociated diseases such as osteopenia and osteoporosis contributing to the increased fragility
of bone.10–12

These degenerative conditions commonly lead to increases in bone and joint

problems ultimately resulting from weak bone.13,14 Non-unions or fractures that occur in
individuals with degenerative skeletal disease may be further affected and more difficult to
treat compared to injuries caused by trauma alone. 15,16
The healthcare system in the United States will be challenged with treating the needs
of the aging population as it relates to bone-related injuries and diseases resulting in bone
damage, degeneration, or loss.12,17 Current treatment options for bone repair and regeneration
(i.e. autografts, allografts, and synthetic materials) present significant limitations and risks and
1

improved treatment methods are necessary. Optimally, a bone graft or bone graft substitute
should provide appropriate mechanical support in addition to providing an osteoconductive
surface for tissue incorporation and remodeling to eventually be replaced by host tissue. While
autografts, which are tissues harvested from the patient, are currently considered the “gold
standard” in bone graft procedures as they represent over half of bone substitutes, they are
limited by available bone volume capable of being harvested and can result in donor site
infection and morbidity. 18,19 Allografts, a secondary option to autografts, are harvested tissues
from cadavers and involve risks of immunogenicity and disease transmission. 15,20,21 To avoid
donor site morbidity, volume availability, potential immunogenicity, and disease transmission,
various bone graft substitutes have been developed although no perfect substitute yet exists
that embodies the autograft’s ideal qualities.22
Current bone graft substitute biomaterials include proteins (i.e. collagen), metals,
plastics, and ceramics manufactured into scaffolds in attempts to mimic the natural
extracellular environment (ECM) by various methods such as electrospinning, hydrogel
formation, microsphere sintering, 3-D printing, thermally-induced phase separation, and
particulate leaching to name a few.23 However, clinical implementation of many biomaterials
has yet to be perfected as they often result in the need for additional surgeries do to fatigue,
fracture, and toxicity of the material. 15 Therefore, a need for replacement methods is needed
to overcome the pitfalls of the current treatments options.
The field of bone tissue engineering has emerged has an alternative and viable option
for bone repair and regeneration. Tissue engineering involves the application of biological,
chemical and engineering principles towards the development of biological su bstitutes for the
repair, restoration, or regeneration of tissue form and function.24 Bone tissue engineering
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comprises of implementing biomaterial scaffolds which are both biodegradable and porous,
with or without the use of bone-forming cells and growth factors, in order to regenerate
bone.25–27 The goal of using a bone graft substitutes is to initiate a healing response from the
host defect area resulting in the production of new bone at both the host-graft substitute
interface and within its porous body. The choice of the biodegradable scaffold used is critical
for the success of bone repair and regeneration as it serves as a temporary and mechanicallystable matrix for cells to infiltrate and proliferate. 25 In addition to the properties of the bone
graft substitute itself such as mechanical stability, for optimal incorporation the vascularity of
the host bed should contain enough pre-osteogenic or osteogenic cells to infiltrate the scaffold
and proliferate.15 Additionally, scaffold pore structure (i.e. pore size and interconnectedness)
plays an essential role in the development process as the nanostructure of the natural ECM acts
as a support system capable of allowing nutrient flow and guiding cellular functions such as
proliferation, differentiation, adhesion, and migration by way of physical cues .28–30
Together, this work focuses on a bone tissue engineering approach using a natural
biomaterial protein, collagen I, fabricated into a hydrogel and characterized with and without
a remote mechanical stimulus using low intensity pulsed ultrasound (LIPUS) to provide an
acoustic radiation force. As bone responds positively to a degree of physical loading des cribed
by Wolff’s Law,31 we hypothesize that the clinical effectiveness of LIPUS in fracture
treatments in part results from the applied load and deformation from the acoustic radiation
force manifested from LIPUS treatment. In addition to developing our own hydrogel scaffold
system for tissue mimetics, we developed and characterized our own highly tunable ultrasound
system. A series of experiments evaluated the response of our adjustable ultrasound system
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to: cells alone; hydrogels alone; cell-hydrogel encapsulation; and cell-hydrogel encapsulation
implantation into a mouse calvarial defect model.

1.2. Bone Biology

The human body consists of groups of cells with a similar structure which work together
for a specific function. These groups of cells are known as “tissues”, and the major types in
vertebrates include nerve, muscle, blood, lymphoid, epithelial, and connective tissues.32 The
tissues contain a unique assortment of cells that are situated within an extracellular matrix
(ECM) composed of macromolecules secreted by cells such as proteins, polymers, and
polysaccharides.

The ECM is responsible for providing structural support to tissues to

facilitate cellular migration, proliferation, and communication. While tissues in the human
body differ in and structure and function, they all work together via intracellular and
extracellular interactions through various signaling molecules such as hormones, proteins, and
biochemicals.33
In vertebrates, bone is a metabolically active and highly organized type of connective
tissue characterized by its robust and mineralized ECM and functions as a structural support
system.

The main functions of bone include providing structural support, vital organ

protection, mineral metabolism, and a site for hematopoiesis. 33 Bone is a very dense and rigid
tissue; however, it is quite dynamic organ that is constantly undergoing a cycle of formation
and resorption during the course of one’s lifetime known as remodeling. Bone’s continual
chemical exchange and structural remodeling are both a result of internal mediators and
external mechanical demands. Bones are vascularized organs that are made of bone tissue,
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bone marrow, and also wrapped in a membrane known as the periosteum, which is a dense and
irregular connective tissue. 34 As stated before, bone is a dynamic organ as it must endure the
daily stresses of activity where it can undergo tension, compression, torsion and shear forces
depending on the location and the individual’s activity.

Fortunately, bone has evolved to

withstand the daily forces acting on it due to its structural integrity and rigidity, but it also
exhibits a degree of flexibility which assists in limiting its failure rate.
Bone can exhibit both strength and a degree of flexibility due to the fact that it i s a
composite material. The main inorganic portion, calcium phosphate (CaP), in the boney tissue
provides the rigidity, while the organic portion of bone, primarily type I collagen (Col I) offers
the flexibility and elasticity. Based on the age of the patient and the activity level, bones are
always adapting to their environment through remodeling so that they can endure the physical
stresses without failure. Bone will form a geometrically optimal shape to carry its mechanical
loads. Bone responds positively to increases in mechanical stress where bone tissue is added
through the process known as apposition, and bone is resorbed where there is a lack of stress.
This phenomenon is known as Wolff’s Law and can be summarized as “bone is deposited and
resorbed in accordance with the stresses placed upon it”.35 There are three main bone cell
types responsible for the makeup of bone tissue and the remodeling process. Oste oblasts are
responsible for synthesizing new bone and ultimately lead to the formation osteocytes once
they become trapped in the matrix that they secrete. Osteoclasts are large multinucleated cells
and are responsible for bone resorption. Bone tissue and cell types are furthered described in
the following sections.
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1.2.1. Structure of Bone

Figure 1. Diagrams of cortical and trabecular bone tissue in long bones showing the inner
structural anatomy.34

As a connective tissue, the structural organization of bone consists of a robust ECM
with a sparse distribution of cells. The mass composition of bone contains 8% water, 22%
protein, and 70% mineral. 33 The non-mineralized organic and mineralized inorganic portions
of bone contain primarily type I collagen (Col I) and calcium phosphate (CaP) respectively.
Furthermore the ECM of bone is comprised of 95% Col I, 5% proteoglycans and various
noncollagenous proteins. 33

The human body consists of 270 bones at birth which later
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Figure 2. Diagram of a long bone showing the different macroscopic sections of bone.36

decreases to 206 bones by adulthood as some bones have fused together. Of these, 126 bones
comprise the appendicular skeleton and 74 bones make up the axial skeleton. 33

The

macroscopic and mechanical properties of the bones in the human skeletal system are
principally influenced by particular loading conditions. Bone structures can be classified as
long (i.e. femur, tibia, etc.), short (i.e. patella, sesamoid, etc.), flat (i.e. skull, sternum, etc.)
and irregular (i.e. vertebrae, sacrum, etc.). Long bones are made of a hollow shaft, or
diaphysis, a flared, cone-shaped metaphysis which lies below the growth plates; and rounded
epiphyses above the growth plate. 36 The diaphysis contains primarily dense cortical bone;
however, the metaphysis and epiphysis contain trabecular meshwork bone surrounded by a
relatively thin shell of dense cortical bone. Within the diaphysis is a medullary cavity
containing bone marrow.
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Bone tissue can be classified as either cortical (compact) bone or trabecular (spongy)
bone as can be seen in the illustration in figure 1. Cortical bone is found on the peripheral
regions of most bones as it forms the cortex, or outer shell, and is dense and highly mineralized
as it exhibits 5-10% porosity, while trabecular bone is commonly found in the end of long
bones and is highly porous with 50-90% porosity.20 Cortical bone is much denser than
cancellous bone. With very few pores it is 80-90% mineralized and accounts for 80% of the
bone tissue in the body by mass. 33 The high density of cortical bone allows it to be well suited
for the mechanical and structural properties of bone as well as to store and release chemical
elements such as calcium. Mechanical loading affects the thickness and density of cortical
bone; however, other factors are involved. Concentric rings of sheets or “lamellae” of densely
packed collagen fibrils account for the cortical bone makeup.
Trabecular, or spongy, bone is found on the interior of bones adjacent to the marrow
cavity or within the ends of long bones. Trabecular bone exhibits less than 10% of the
compressive strength as well as less than 5% of the compressive modulus of cortical bone. 37
However, trabecular bone exhibits higher surface area than cortical bone and is important for
bone functions such as calcium homeostasis as well as acid/base regulation.

A fibrous

connective tissue sheath surrounds the outer cortical surface of bone known as the periosteum
(figure 2).

The periosteum contains blood vessels, nerve fibers, and osteoblasts and

osteoclasts.

Additionally, the periosteum has bone regenerative capabilities as its bone

formation continues to be active through the course of one’s lifetime. Vasculature and nerves
are supplied to bones via the periosteum as well as attachment sites for surrounding tendons
and muscles. The periosteum works during fracture healing by promoting the formation of
cartilaginous callus, followed by ossification. 38 Another membranous structure known as the
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endosteum covers the inner surface of cortical bone, trabecular bone, and the blood vessel
canals present in bone known as Volkmann’s canals. The endosteum contacts the bone marrow
space, trabecular bone, and blood vessel canals and contains blood vessels, osteoblasts, and
osteoclasts. The main unit of bone is known as the osteon. Cortical and trabecular b ones are
composed of osteons. 20 The osteons in cortical bone are called Haversian systems. Lamellae
of continuous collagen fibril roughly 50-500 nm arrange in concentric manners around a
central Haversian canal to form osteons or Haversian systems in cortical bone. 20 The canals
contain blood vessels which supply nutrients throughout the bones.

Bone cells and

development will be discussed in the following sections.

1.2.2. Bone Cells

There are several distinct cell types involved in the formation and remodeling of bone
tissue. The types of bone cells and where they can be found within bone tissue are osteoblasts,
osteocytes, and osteoclasts as seen in figure 3 and are derived from stem cells.39 Osteoblasts
and osteoclasts are found on the surfaces of bone, while osteocytes permeate the mineralized
interior.40 Osteoblasts are fully differentiated bone cells whose roles include the synthesis of
bone matrix on the bone forming surfaces and regulation of matrix mineralization. 40
Osteocytes are terminally differentiated osteoblasts that are encased by the mineralized matrix
and help support overall bone structure. Osteoclasts are large, multinucleated cells derived
from different cellular precursors (hematopoietic stem cells), and are responsible for the
mechanism of bone resorption. 40

9

Figure 3. Diagram of types of bone cells and where they reside.39

Many specialized cell types including nerve, intestinal lining, and bone cells are
incapable of renewal by cell division. Rather, these specialized cells are formed from adult
stem cells, which have the ability to differentiate into one (unipotent) or many (pluripot ent)
types of terminally differentiated cells. An embryonic stem cell is one derived from human
embryos and is capable of differentiating into any type of cell when supplied the appropriate
environmental conditions and stimuli. 32 In contrast, while an adult stem cell is not terminally
differentiated, its fate is determined in such that it has undergone an internal chemical change
that distinguishes it and its progeny from embryonic stem cells. 32 Embryonic stem cells arise
during embryonic development where three germ layers are formed: the ectoderm; the

10

mesoderm; and the endoderm. As the prefix in the name implies, the mesoderm is the middle
germ layer consisting of multipotent mesenchymal stem cells which eventually give rise to the
vascular and lymphatic systems as well as all connective tissue. 32 Mesenchymal stem cells are
a class of multipotent mesoderm-derived stem cells that can be induced to differentiate into
osteoprogenitors that ultimately can become osteoblasts, osteocytes, and bone lining cells. As
stated before, hematopoietic stem cells can differentiate into osteoclasts and are also of
mesoderm origin, but are multipotent in the sense that they give rise to all formed elements in
the blood and immune system. 41
Osteoblasts are fully differentiated cuboidal cells derived from preosteoblasts or
osteoprogenitor cells, which are progenitor cells derived from mesenchymal stem cells located
in the bone marrow or the periosteum.33 A preosteoblast is stimulated to differentiate into an
osteoblast via soluble factors including bone morphogenetic proteins (BMPs) and wingless-int
proteins (Wnt).42 The expression of Runt related transcription factors 2 (RUNX2), Distal-less
homeobox 5 (Dlx5), and osterix (Osx) are necessary for osteoblast differentiation. 33 Also,
RUNX2 is a known as a master gene for osteoblast differentiation due to the fact that RUNX2 null mice lack osteoblasts. As the preosteoblasts have been stimulated to differentiate, they
cease proliferation and begin to secrete proteins indicative of osteoblast phenotype. New
osteoblasts are located at the surface of developing bone tissue and exhibit a cuboidal
morphology. Osteoblasts actively secrete unmineralized osteoid matrix at the location of
newly forming bone containing the organic portion of bone ECM primarily composed of
collagen type I which makes up approximately 90% of the matrix.43 The remainder of the
osteoid matrix is made of proteoglycans and noncollagenous proteins including osteopontin,
osteocalcin, and osteonectin. When the osteoid matrix is being actively produced in addition
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to the presence of membrane protein alkaline phosphatase, the osteoblast phenotype is present.
Eventually the osteoid matrix around the osteoblast will calcify and roughly 20% of the
embedded osteoblasts transition to osteocytes.44

Any osteoblasts that do not ultimately

transition to osteocytes will undergo apoptosis, or cellular death.
As discussed osteocytes are terminally differentiated cells derived from mature
osteoblasts that have become embedded within the calcified matrix. As osteocytes account for
90-95% of the total bone cells, they are the most abundant and long-lived cells capable of a
lifespan up to 25 years. 33 Osteocytes are derived from mesenchymal stem cells lineage through
osteoblast differentiation with four recognizable stages having been proposed: osteoid osteocyte, pre-osteocyte, young osteocyte, and mature osteocyte.45 During the transformation
from an osteoblast to an osteocyte, the expression of many of the proteins indicative of an
osteoblast phenotype including type I collagen, alkaline phosphatase, osteocalcin, and bone
sialoprotein, are no longer produced.33,45

Also, osteocytes produce a network amongst

themselves by extending many long processes to adjacent osteocytes known as the lacunar canalicular network. This network is used for nutrient and waste transfer in addition to
communication between the osteocytes via gap junctions.45 As the osteocyte cell body resides
in the lacuna, the osteocyte’s processes extend out through the canaliculi to adjacent osteocytes
and Haversian canals. These Haversian canals are responsible for supplying vasculature in
order to deliver and remove nutrients.

A concentric arrangement of lacunar-canalicular

network of osteocytes surrounding a Haversian canal is known as an osteon.33 Importantly,
osteocytes

have

been

believed

to

be

the

primary

mechanosensors

in

bone.

Mechanotranduction, or a mechanism in which cells convert a mechanical stimulus into an
electro-chemical activity, is believed to be initiated by fluid flux within the canaliculi resulting
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from pressure gradients between lacunae when the bone is loaded. 46 Fluid motion triggers
depolarization of the osteocyte process and can propagate to other osteocytes via gap junctions.
Mechanotransduction in osteocytes contributes to recruitment of osteoblasts or osteoclasts
depending on the particular nature of the loading condition.46–48
Osteoclasts are multi-nucleated cells derived from hematopoietic stem cells as opposed
to mesenchymal stem cells which give rise to osteoblasts and ultimately osteocytes.
Osteoclasts are responsible in bone metabolism for the resorption of bone and exhibit a
polarized plasma membrane. Osteoclasts exhibit a polarized plasma membrane which aids in
resorbing bone. Two distinct plasma membrane regions are found on the basal surface of the
osteoclast: a ruffled portion of the plasma membrane which is the location of where resorption
of the bone occurs; and a sealing region that binds the ruffled border to the bo ne extracellular
matrix.49 A resorption lacuna is the combination of the ruffled and sealing regions of the
plasma membrane. An osteoclast initially dissolves the mineralized portion of the bone matrix
by secreting hydrochloric acid. Once the mineral content is removed, the protein content of
the matrix is degraded by proteolytic enzymes. Contents are transported through the osteoclast
in vesicles that are emptied into the extracellular space for use elsewhere. 49–51

1.2.3. Bone Tissue Development

Calcified bone tissue can be formed by two distinct modes of ossification, also known
as calcification, classified as either intramembranous ossification52 (figure 4) or endochondral
ossification39 (figure 5). The type of bone being formed dictates the method of ossification.
Flat and irregular shaped bones are formed through intramembranous ossification where long
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Figure 4. Diagram showing the stages of intramembranous ossification. 52

bones are formed via endochondral ossification.33,53,54 Intramembranous ossification starts
without a pre-existing cartilage model, instead, mesenchymal stem cells form clusters. These
stem cells then differentiate to osteoblasts which in turn start to secrete an osteoid matrix which
is calcified to form bone spicules. The osteoblasts which become trapped within the bone
spicules either terminally differentiate to osteocytes or undergo cell death via apoptosis. Bone
spicules radiate outward from the origin of the mesenchymal stem cell cluster. Spicules
ultimately join together to create a layer of calcified bone. The periosteum is formed by
mesenchymal stem cells apical to the calcifying tissue differentiating.

However, the

mesenchymal stem cells basal to the calcifying tissue differentiate to osteoblasts which for m
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subsequent layers of calcified tissue. This resulting bone tissue is classified as woven bone
which is formed quickly and characterized by randomly oriented collagen fibrils, yet it is not
as mechanically viable as lamellar bone.33,43,54

Figure 5. Diagram showing the stages of endochondral ossification. 39

The other type of bone formation known as endochondral ossification occurs in several
steps starting with a preexisting cartilage template which begins to be calcified. As this
cartilage template becomes calcified, the chondrocytes in the cartilage become hypertrophi c
and undergo apoptosis.33,53 Afterwards, mesenchymal stem cells in the membrane surrounding
the calcifying cartilage, or periosteum, differentiate into osteoblasts. The osteoblasts secrete
an osteoid matrix around the exterior of the cartilage template while a bud of cells originating
from the periosteum invades the interior of the partially calcified cartilage template. This
periosteal bud leads to vascularization and also innervation of the developing bone as well as
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supplying mesenchymal and hematopoietic stem cells into the center of the cartilage template.
As previously discussed, the mesenchymal stem cells differentiate to osteoblasts, and the
hematopoietic stem cells differentiate to osteoclasts. The osteoblasts and osteoclasts are
responsible for remodeling the partially calcified cartilage into woven bone, resulting in
ultimately being remodeled to become lamellar bone. Lamellar bone is characterized by
collagen fibrils arranged in parallel areas and exhibits greater strength in comparison to woven
bone.33 The bone tissue created from the cells originating from the periosteal bud increases
and eventually radiates outward to join the bone tissue created by the osteoblasts on the surface
of the cartilage template.55

1.3. Fracture Healing and Bone Repair

Figure 6. Diagram showing the stages of the fracture healing process.52

Fractures occur when a force exceeds the mechanical integrity of the bone. Fracture
healing is a natural process that can restore the bone to the pre-fracture state function and
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mechanical integrity without the formation of scar tissue as seen in figure 6. Broken or
fractured bone heals by a mechanism greatly different from the way in which damaged soft
tissue is healed. Also, the healing method of bone is indicative of the type of bone damaged
(cortical or cancellous). Interestingly, bone is repaired by a process that reiterates many of the
events in both intramembranous and endochondral bone formation. Fractured cortical bone is
repaired by a callus formation mechanism, in which new bone (callus) composed of fibrous
tissue, blood vessels, cartilage, and bone forms in order to bridge the gap between the two
fractured bone fragments. 56 Fracture healing occurs in four main stages that temporarily
overlap: 1) the early inflammatory stage (hematoma); 2) soft callus formation; 3) hard callus
formation; and 4) the remodeling stage.43,57

1.3.1. Inflammation

The first stage of bone healing is inflammation which is immediately induced by the
disruption of the endosteum, periosteum, soft tissue, and blood vessels from the incurred
injury. A coagulation cascade is activated as vasoactive mediators and necrotic tissue released
resulting in the promotion of blood vessel dilation near the damaged site. The blood that flows
from the severed vessels results in the formation of a hematoma at the fracture site containing
debris of soft tissue and living and dead bone cells resulting in the recruitment of many
signaling molecules involved in the regulation of new bone formation (i.e., ILs, TNF-α, FGFs,
BMPs, PDGF, VEGF, etc.).33,58 Hemostasis is achieved within the hematoma as platelets bind
to the fibrillar collagen that forms throughout the site resulting in cell migration, prolife ration,
and differentiation. New blood vessels are formed from preexisting ones via a process known
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as angiogenesis within the hematoma as inflammatory cells, fibroblasts, and preosteoblasts are
recruited by growth factors and cytokines released by the inflammatory response.43 In theory,
each population of cells recruited to the fracture site releases a collection of growth factors
responsible for additional recruitment of the following cell populations developing a
recruitment cascade that sequentially brings the appropriate precursors for new
musculoskeletal formation.58

1.3.2. Soft Callus Formation

The second stage of cortical bone healing is a soft (or primary) callus formation, which
includes the formation and organization of fibrous granulation tissue at the site of the fracture
which is eventually replaced by mineralized bone in the following stages. During this stage,
chondrocytes and fibroblasts produce a semi-rigid soft callus that is able to provide mechanical
support for the fracture in addition to serving as a template for the bony callus that will later
follow it.

The formation of new bone tissue may proceed by either direct or indirect

ossification, or intramembranous and endochondral ossification respectively.59 Generally, the
external callus which forms around the periosteum proceeds through intramembranous
ossification where pre-existing osteoblasts on the ends of the fracture site proliferate rapidly
and directly lay down new bone. In contrast the internal callus undergoes endochondral
ossification as fibrocartilage is initially formed and subsequently replaced by min eralized,
osteogenic tissue.58 The growth of the separated cartilaginous regions continues until they
unite to generate a big fibrocartilaginous callus which bridges the fracture. Recruited stem
cells and fibroblasts from the inflammatory response contribute to the formation of the new

18

bone, cartilage, fibrous tissue, and blood vessels. Regulation of these cells is controlled by
signals from growth factors, hormones, pH, and the mechanical environment.58

1.3.3. Hard Callus Formation

The third stage of fracture healing is known as hard (or secondary) callus formation,
which occurs as hard woven bone replaces the newly synthesized young bone that composes
the soft callus. This stage is the most active osteogenic period. High levels of osteoblast
activity contribute to the formation of mineralized bone matrix, which arises directly in the
peripheral callus. The insecure soft callus is gradually removed followed by revascularization
to allow for bridging new hard callus to form. This new bone is known as the hard callus
which is characterized typically by irregular and under-remodeled bone tissue; however, it has
an increased diameter compared to the original cortex and therefore provides sufficient
stability to the defect site. The hard callus formation stage in the fracture healing process, also
termed primary bone formation, displays the most rapid osteogenesis which involves: 1) bone
cell recruitment and subsequent woven bone formation; 2) chondrocyte apoptosis, osteoclast
recruitment, and mineralized cartilage resorption; and 3) continued neo-angiogenesis.58

1.3.4. Bone Remodeling

After the formation of the woven bone hard callus, the final remodeling stage of fracture
healing known as bone remodeling occurs over 12 weeks as the hard callus is gradually
remodeled to lamellar bone and the size of the callus is decreased to that of pre-existing bone.
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The new bone gradually undergoes a restructuring process that is indicative of the local applied
physiological stresses, hence new bone can assume the optimal structure and vasculature to
support the mechanical and metabolic needs of the tissue reestablished.57 This renewal process
is achieved by small pockets of old bone being replaced by new bone. In humans , it is
estimated that as much as 25% of trabecular bone and 3% of cortical bone is resorbed and
replaced each year.60 Any several humoral or local stimuli of resorption initiate the appearance
of osteoclasts and precursors at the remodeling site. The osteoclasts then resorb an amount of
bone which produces a small resorption pit known as Howship’s lacuna, where they
subsequently move on to another site.

Figure 7. Diagram showing the process of bone remodeling.39

An active reversal of the resorption phase occurs when a cement line is deposited also
known as the reversal phase. A subsequent formative phase occurs as actively synthesizing
cuboidal osteoblasts appear and begin to deposit uncalcified matrix known as osteoid which is
later mineralized. Resorption and formation always occur successively in the same location
as well as in the same order (figure 7). The sequence of resorption and formation described
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has been referred to as a basic multicellular unit of bone turnover (BMU). 61 The term coupling
refers to when the process of bone resorption is followed by an equal amount of bone
formation. The total length of time of the remodeling phase can be from 3 months to several
years for full completion.60

1.3.5. Growth Factors Associated with Bone Healing

Cells receive information from growth factors through the binding of a factor to its
receptor which is integrated in the cell’s plasma membrane. Each receptor is specific for
binding of a particular factor which binds with a high affinity resulting in the stimulation of
an intercellular response. Once the factor is bound to the receptor, transmission to the cell
may occur in several different ways, depending on the particular factor and its function.
Researchers have isolated many of these growth factors for further study and/or incorporation
into treatments (i.e. scaffold design, etc.) for bone tissue engineering applications. 58,62–64 Bone
healing is a very intricate phenomenon that involves many different steps and factors
throughout its process. A summary of commonly studied growth factors associated in the
fracture healing process are discussed below for the various bone healing stages.
After a fracture occurs, a blood clot forms at the injury site where platelets release
granules to transform the clot into a hematoma. The formation of a hematoma creates an ECM
allowing for inflammatory cells such as neutrophils, monocytes, and lymphocytes to have
access to the hematoma. Additionally, mesenchymal stem cells (MSC’s) are recruited to the
site of the fracture within hours of occurring. The recruited cellular response is regulated by
secretion of a range of cytokines and growth factors including transforming growth factor -β

21

(TGF-β), platelet-derived growth factor (PDGF), fibroblast growth factor-2 (FGF-2), vascular
endothelial growth factor (VEGF), macrophage colony stimulating factor (MCSF),
interleukins-1 and -6 (IL-1 and -6), bone morphogenetic proteins (BMPs), and tumor necrosis
factor-α (TNF-α).64

The factors work in a positive feedback loop to recruit additional

inflammatory cells in addition to the migration and invasion of multipotent MSC’s.
During the second stage of healing, MSC’s are differentiated into chondrocytes
resulting in the formation of cartilage.

Fibroblast proliferation and chondrocyte

proliferation/differentiation occur via a coordinated expression of the following growth
factors: TGF-β2 and -β3, PDGF, FGF-1, and insulin-like growth factor (IGF).

Cell

proliferation and chondrogenesis is also regulated by various factors in the BMP family. The
soft callus is subsequently invaded by vascular endothelial cells, angiogenesis, and capillary
in-growth via stimulation by pro-angiogenic factors such as BMPs, VEGF, FGF-1 and TGFβ. During the hard callus formation, or primary bone formation, an increase of factors TNFα, receptor activator of nuclear factor kappa B ligand (RANKL), and macrophage colonystimulating factor (MCSF) are responsible for mineralized cartilage resorption, the recruitment
of MSCs, and induction of apoptosis of hypertrophic chondrocytes. Additionally, various
members of the BMP family such as BMP-3, BMP-4, BMP-7, and BMP-8 are upregulated in
conjunction with resorption of calcified cartilage and aid in recruiting cells in of the
osteoblastic lineage. Upregulation of VEGFs stimulate new blood vessel formation, or neo angiogenesis. In the final stage of bone healing, the remodeling phase, both osteoblasts and
osteoclasts work in combination for the production of secondary bone resulting in the
restoration of the bone to its original size, shape, structure, and level of functional ity. During
this final stage of bone healing, factors IL-1 and IL-6 are upregulated, whereas expression
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levels of RANKL, MCSF, and TGF-β gradually decline. In order for the proper bone healing
process to occur, the cascade of events occurs by the presence and activation of the appropriate
growth factors and cytokines at the specific and appropriate time points. A summary of these
growth factors and cytokines for each of the four stages of bone healing can be seen in table
1.63,64

Cytokines/Growth Factor
• IL-1, 6

Bone healing stage
1. Inflammation

Overall action
• Hematoma

• TNFα

• Inflammation

• PDGFs

• MSCs recruitment

• GDF-8
• RANKL, MCSF
• OPG
• VEGFs

• Chondrogenesis

2. Soft callus

• TGFβs

• Endochondral ossification

• BMPs

• Osteoblast/osteoclast

• Angiopoietin

precursors recruitment

• FGF-I

• Vascular ingrowth

• IGF

• New angiogenesis

• VEGFs

• Cartilage resorption

3. Hard callus

• BMP-2, 7

• Chondrocyte apoptosis

• RANKL, MCSF

• Osteoblast/osteoclast

• Angiopoietin

precursors differentiation
• Woven bone formation
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• IL-1, IL-6

• Bone remodeling

4. Remodeling

• RANKL, MCSF

• Marrow establishment
• Osteoblast activity

Table 1. Growth factors associated with fracture healing. 63,64

1.3.6. Osteogenic Markers

Figure 8. Expression of osteoblast markers relative to culture time in respect to their
contribution to different phases of bone formation. 65

Various osteoblast markers are responsible for cell differentiation and matrix
mineralization over time as can be seen in figure 8. Expression levels of calcium, osteocalcin
(OCN), osteopontin (OPN), alkaline phosphatase (ALP), collagen type I (Col I), and core
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binding factor alpha-1 (cbfa1), also known as Runx2, vary over time during osteoblastic
differentiation, proliferation, and matrix mineralization. 65 Understanding when differentiating
osteoblasts express each specific marker allows for understanding of a cell’s approximate stage
within osteoblastic development. Mesenchymal stem cells begin culture in a proliferative
phase and continue to differentiate into osteoblasts during matrix maturation and
mineralization. During this period, the mesenchymal stem cells produce the various proteins
and growth factors in a temporal pattern that is indicative upon their functional activity. 33 As
the osteoblastic markers expression were of interest to this work particularly relating to
ultrasound treatment and mechanical environment, each marker will be discussed further in
the following sections.

1.3.6.1.

Alkaline phosphatase (ALP)

Alkaline phosphatase (ALP) in bone is a glycoprotein located on the cell membrane of
osteoblasts and is known to be the most commonly measured phenotypic osteoblast marker. 66
However, ALP is found in several other non-mineralized tissues including liver, kidney,
intestine, and placenta. ALP is an enzyme that hydrolyzes phosphate esters from a number of
different types of molecules including proteins and nucleotides, and received its name
according to its enhanced activity at high pH levels. 33 ALP has been shown to be important to
the process of bone mineralization. Literature has shown evidence of disease states lacking
ALP resulting in abnormal or lack of mineralization. Hypophosphatasia, a potentially lethal
syndrome that causes abnormal mineralization of the skeleton, results from a missense
mutation in the ALP gene. 67

Additionally, ALP-lacking cells hence incapable of
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mineralization can be transfected with the gene for ALP in vitro resulting in the acquired ability
to mineralize.68 ALP gene expression generally begins when a cell transitions from the
proliferative to the matrix maturation stage, peaks during matrix maturation, and then
decreases upon entrance of the osteoblastic mineralization stage.

The role of ALP in

mineralization can be summarized by the following: 1) ALP hydrolyzes phosphate ester and
results in the increase of local phosphate concentrate ultimately promoting bone mineral
formation; 2) ALP hydrolyzes pyrophosphate, a calcification inhibitor, into phosphate
molecules; 3) ALP transfers phosphate groups from the extracellular fluid and binds calcium
to facilitate calcium phosphate precipitation.69,70

1.3.6.2.

Osteocalcin (OCN)

Osteocalcin (OCN) is a calcium-binding protein that is the most abundant noncollagenous protein in bone tissue. While the exact role of OCN is not completely understood,
it is known to have a role in the process of bone mineralization, during which it binds to
calcium phosphate in the ECM of osteoblasts. 71,72 It is exclusively produced by osteoblasts
and odontoblasts, and its function is dependent on vitamin K. 73 OCN is primarily synthesized
during the matrix mineralization stage of osteoblastic development, but may be marginally
produced at earlier stages of matrix mineralization. 33 Additionally, it has been suggested that
OCN acts as a chemoattractant for osteoblasts, osteoclasts, and blood monocytes. 73
Importantly, most of an organisms OCN is localized within the bone cell matrices; however,
when osteoblasts are producing large amounts of OCN during the mineralization phase of
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osteoblastic development, some OCN is also emitted into the blood. For this reason, serum
levels of OCN are considered to be indicative of new bone formation.

1.3.6.3.

Osteopontin (OPN)

Osteopontin (OPN) is a secreted glycoprotein that was originally found in osteoblasts
and is produced by a variety of cells including preosteoblasts, osteoblasts, osteocytes,
endothelial cells, and macrophages, and its synthesis is stimulated by vitamin D3. 33 OPN has
been shown to have a strong affinity for calcified matrix such as bone. 74 When OPN is
modified via transglutamation, it binds covalently to collagen type I. 75 In bone, OPN is
generally synthesized by osteoblast-lineage cells and incorporated into the extracellular
matrix. OPN is synthesized by preosteoblasts late in the proliferation stage, and by osteoblasts
throughout the matrix maturation and mineralization stages. 33 While the function of OPN in
bone is not completely understood, it is thought to be related to the process of bone resorption
due to its proven interactions with osteoclasts 76 and supportive role for their function in mineral
resorption.77 As the molecular conformation of OPN is altered by calcium-binding in a Ca2+
concentration-dependent manner, the binding-dependent conformation change has been
suggested to expose various binding motifs that resultantly modulate the protein’s activity.
This modulation ability is thought to directly affect the process of osteoclast -mediated bone
resorption.33
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1.3.6.4.

Collagen type I (COLI)

Collagen is the primary protein in a number of animal tissues, including bone, cartilage,
tendons, and teeth. Overall, it constitutes approximately 25% of the entire protein content in
mammals.78 Collagen is a long, fibrous protein found in the extracellular matrices of cells that
functions as a mechanical support for tissues. The structure of a collagen molecule consists of
triple helix subunit that is made up of three polypeptide strands. These strands are each lefthanded helices that are wound together into a right-hand coiled coil stabilized by hydrogen
bonding; a configuration that gives collagen its characteristic strength. 79,80

Triple helix

subunits are wound together in multiples to make collagen fibrils, which can further be
assembled into collagen fibers. 33 Various types of covalent cross-linking between triple
helices distinguish the 28 different types of collagen that have been identified; however, nearly
90% of the collagen in the body is made up of collagen types I-IV.
Collagen type I (COLI) is the most abundant form of collagen in the human body and
constitutes a major component of osteoblast extracellular matrices. 33 As bone tissue is a
composite made up of organic (proteins) and inorganic (CaP) components, the unique structure
of collagen provides bone tissue with elasticity and helps to prevent fractures under applied
stress. Bone tissue contains collagen type I triple helices that are covalently crosslinked and
arranged in parallel with 40 nm gaps between the ends of adjacent molecules. 81 In the
extracellular space, collagen molecules are attached to cell membranes with the hel p of a
number of different proteins such as fibronectin and integrin. 82 Collagen type I triple helices
are composed of two different chains called pro-alpha1(I) and pro-alpha2(I), which are coded
for by two different genes, named COL1A1 and COL1A2, respectively. 33 While the chains
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are manufactured inside of the cell, they must be processed extracellularly to form the triple
helix with the help of enzymes.

The majority of collagen type I is produced by late

preosteoblasts and osteoblasts during the process of matrix formation.33

1.3.6.5.

Core binding factor alpha-1 (cbfa1) (RUNX2)

Core binding factor alpha-1 (cbfa1), or Runx2, is a transcription factor thought to be
the primary control switch for the production of various osteoblastic marker proteins such as
alkaline phosphatase, collagen type I, osteocalcin, and osteopontin. 83

It is the only

transcriptional factor that is specifically expressed in osteoblastic lineage cells and is thought
to be the earliest specific marker of osteogenesis. 33 Runx2 is part of the Runt family of
transcription factors and has been documented to be essential to the differentiation of
mesenchymal stem cells into mature osteoblasts. 84,85 While the exact functional role of Runx2
is still not fully understood, growth factors and biochemicals such as transforming growth
factor-β (TGF-β), dexamethasone, and bone morphogenetic growth factor-2 (BMP-2) have
been shown to increase primary human osteoblastic cbfa1 mRNA levels in vitro. 86
Additionally, another studied showed that mice lacking cbfa1 were completely unable to form
bone and contained osteoblasts that lacked osteocalcin and osteopontin, two noncollagenous
matrix proteins responsible for matrix maturation and mineralization. 87
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1.4. Bone Grafts and Bone Graft Substitutes

While bone is highly vascularized and has the ability to regenerate, beyond a critical
point, clinical intervention is required for successful healing. Besides fractures, other large
scale defects can result from sources such as trauma or cancer. Additionally, mal-unions, nonunions, or fractures occur at a higher rate in people with degenerative skeletal diseases
resulting in more difficulty in treating the injuries as opposed to trauma alone. It comes as no
surprise that bone is one of the most commonly transplanted tissues, ranking at second in the
world.22 Critical defects are voids in the bone that are too big to heal by the body’s natural
process requiring intervention such as bone grafts or bone graft substitutes. Some of the
criteria for the ideal bone substitute which is also sought after in bone tissue engineering
applications discussed later are osteoconductivity, osteoinductivity, osteogenicity, and
immune-compatibility.

1.4.1. Autografts

Autografts are currently considered the gold standard for enhanced bone healing as they
provide patient-specific tissue and the best chances of successful healing without immuno rejection or other complications through possessing optimal biocompatibility, biological
components, and pore structure. Bone grafts are taken from a healthy site and placed into
another site within the same individual. However, autografts have a major limitation as there
is only so much tissue that can be harvested from one patient in addition to the need for an
additional surgical site which can lead to infection, post-operative pain, and donor site
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morbidity. Autologous bone contains osteoblasts and osteoprogenitor cells capable of making
new bone, as well as the intact ECM and embedded bioactive proteins/molecules, which makes
autologous bone the most suitable choice for bone repair. Importantly, cells typically retain
their viability after implantation of the autologous tissue.

No adverse immunogenetic

responses are associated with autografts as the ability of the graft to be incorporated into host
tissue is highly enhanced.88 Lastly and importantly, there is no risk of disease transmission
with autologous tissue.
Autologous bone grafts can be obtained from various bones sources such as iliac crest,
tibia, radius, and humerus.88,89 The iliac crest is the most commonly used donor site due to
easy accessibility and the amount of bone available; however, harvesting autologous bone can
cause significant donor site morbidity which results in further complications. Donor site
morbidity occurs in approximately 20% of all cases.23,90 When large amounts of bone are
needed, the necessary amounts of autograft may not be available from the host. In this case,
other bone graft materials must be considered.

1.4.2. Allografts

Allografts are the next choice in line for bone graft procedures as they are tissue
harvested from one individual and implanted into another individual; however, these run the
risk of disease transmission or immune-rejection. 88 Considering the limitations of autografts,
allografts are used clinically as a common alternative. Bone allografts can be obtained through
regional tissue banks and are used as fragments. Bone allografts are used as fragments, in
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powder form and in solid forms and are provided as cortical, cancellous, or cortico-cancellous
grafts, similar to autografts.15
Allografts are processed as demineralized, fresh, frozen, or freeze-dried forms of bone.
There is greater availability of allografts, as they are usually isolated from cadavers.91 The
major advantages of allografts therefore lie in their availability in different shapes and sizes,
and avoidance of donor site morbidity. Major disadvantages of allografts include the risk of
transferring bacterial and viral diseases, such as human immunodeficiency virus (HIV) and
hepatitis viruses. In addition, since they are not autologous, they may induce unwanted
immunological responses that could disrupt the bone healing process, and may ultimately lead
to rejection of the graft.91,92
Allografts from harvested from fresh cadavers undergo very little processing resulting
in the preservation of their cellular and organic content. However, fresh bone allografts may
present clinical challenges given the higher chance of immune response associated with this
type of graft (host cells attacking the transplanted tissue) and the increased risk of disease
transmission. Methods for sterilization and storage, such as freeze-drying or treating the grafts
with hypotonic solutions (e.g. acetone) or gases (e.g. ethylene oxide), which can remove
bacteria and viral particles, result in a decreased risk of disease transmission.93–95 A drawback
of these processes is that they may denature/destroy the proteins within the allograft
consequently reducing the osteoinductive capacity.88,92 As a result, freeze-dried allografts,
when compared to autografts, take more time for cellular migration and infiltration. In
addition, this method also reduces the biomechanical properties of the graft. Due to these
disadvantages of allograft processing, more suitable materials are required for bone grafting.
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1.4.3. Bone Graft Substitutes

Class

Description

Allograft-based

Allograft bone used alone or in combination with other
materials

Factor-based

Natural and recombinant growth factors used alone or
in combination with other materials

Cell-based

Utilize cells to generate new tissue either alone or
seeded onto a support matrix

Ceramic-based

Includes calcium phosphate, calcium sulfate, and
bioactive glasses used alone or in combination

Polymer-based

Both degradable and non-degradable polymers used
alone and in combination with other materials

Table 2. Description of classification system for bone graft substitutes. Many of the
currently available bone graft substitutes fall within one or more of the above-described
groups. 92

Bone grafts and bone graft substitutes can be used alone or in conjunction with other
additives to increase successful incorporation. There are several categories of bone graft
substitutes encompassing varied materials, material sources, and origin (natural vs. synthetic).
A bone graft classification system, described in table 2, has been developed to describe these
groups based on their material makeup.92 Allograft-based bone graft substitutes can be used
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alone or in combination with other growth factors or materials. Additionally, natural and
recombinant growth factors are another source and can be used alone or in combination with
other materials. The utilization of cells, of particular interest, various stem cell types, to
generate new tissue either alone or seeded onto a support matrix provides another feasible bone
graft substitute option. Various ceramics such as calcium phosphates and bioactive glasses
used alone or in other combinations are another viable option for bone graft substitutes as they
can mimic the inorganic portion of native composite bone tissue if they are fabricated in an
optimal way. Polymers are another viable option as a bone graft substitute as they are
relatively easy to manufacture and can be degradable or nondegradable depending upon their
application for use. Lastly, hydrogels, such as collagen, serve as another alternative and may
be useful for cell encapsulation and allow for degradation where the bone cells own
extracellular matrix may secure the growth of a new extracellular matrix to replace the initial
suspended structure. Further discussion of each class of bone graft substitutes is provided in
the following sections.

When considering the selection of biomaterials for bone graft

substitutes, a few key properties are worth noting including biocompatibility, biodegradability,
mechanical properties, osteoconductivity, osteoinductivity, osteointegrity, osteogenicity, and
porosity. These terms are defined below. 92

Biocompatibility – Biocompatible grafts do not elicit an immune response, and therefore
minimize the host’s natural tendency to eliminate the foreign species.
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Biodegradability – Biodegradable scaffolds are capable of gradual decomposition so that
newly formed tissue may appropriately fill in the defect site, and therefore eliminate the need
for a second surgery to remove the original graft.

Mechanical properties – A graft should have the mechanical properties that are similar to
those of the native bone. While a weak graft may not have sufficient load-bearing
capabilities, an overly strong graft may result in stress shielding that could lead to the
resorption of the newly forming bone.

Osteoconductivity – This property refers to a graft’s ability to support the attachment,
proliferation, and migration of new osteoblasts and osteoprogenitor cells onto its surface and
has an interconnected pore system that allows these cells and others to migrate throughout
the structure.

Osteoinductivity - This property describes the ability of a graft to induce non-differentiated
stem cells or osteoprogenitor cells down the osteoblastic lineage. A graft may possess this
capability via the addition of growth factors or other inductive agent.

Osteointegrity – An osteointegrative graft can bond to the surrounding tissues through new
tissue growth and/or mineral formation. A graft stably fixed in position is necessary to direct
the proper localized bone formation while accepting the required mechanical responsibilities.

Osteogenicity – An osteogenic graft is one that is cellularized with osteoblast-lineage cells,
and furthermore supports the mineralization of the cells’ collagen-based ECMs.
35

Porosity – An appropriate and interconnected pore structure provides a means for cellular
migration and to transfer nutrients and waste between the cells on the scaffold and the
surrounding environment. Without proper molecular transport, cells become starved of
required nutrients and poisoned with generated toxins.

1.4.3.1.

Allograft-based

Prior to the 1980’s, allograft tissue was mainly used as a substitute for autografts for
large defect sites.

However, since then the use of allograft tissue has increased from

approximately 5,000-10,000 cases in 1985 to almost 150,000 cases in 1996. 96 Between
methods of donor screening and tissue processing, risk of disease transmission from allograft
tissue has been reduced and therefore become a more attractive alternative to the autograft. As
the clinical acceptance of allograft tissue has increased, numerous products have emerged that
are allograft-based but also used in combination with other materials and/or growth
factors.6,92,97,98
Demineralized bone matrix (DBM) is another clinically used bone graft substitute
produced by acid extraction of allograft cortical bones.99,100 DBM is attractive as it exhibits
both osteoinductive and osteoconductive properties. 6,15,89,100 The effectiveness of DBM comes
in part due to the osteoconductive scaffold in addition to osteoinductivity provided by the
presence of endogenous growth factors including bone morphogenic proteins (BMPs),
fibroblast growth factor 2 (FGF-2), insulin growth factor 1 (IGF-1) and tumor growth factor
beta (TGF-β).99,100 Additionally, DBM serves as an effective cell carrier as it does not
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stimulate a large immunological response from host cells from the removal of antigenic surface
structure of bone during the demineralization processing. DBM has exhibited angiogenic
properties as it has been shown to vascularize fairly quickly. 101 Various commercial forms of
DBM are available clinically including powder, granules, gel, putty, and strips , and additional
products are currently under FDA approval or review. Similar to allografts, osteoinductive
potential of DBM can be affected by processing methods, sterilization, and storage.
Additionally, as DBM is an allogenic material, risk of disease transmission such as HIV ex ists
similar to allografts.99,100 Another drawback to DBM is structural integrity due to its poor
mechanical properties.

1.4.3.2.

Factor-based

Factors and proteins in bone are responsible for regulating cellular activity by binding
to receptors on cell surfaces resulting in the stimulation of the intracellular environment.
Generally, this translates to a protein kinase that induces a series of events resulting in the
transcription of mRNA and ultimately into the formation of a protein to be used intra- or extracellularly. Many factors act simultaneously on a cell which results in the controlled production
and resorption of bone.

Factors residing in the extracellular matrix of bone include

transforming growth factor-β (TGF-β), insulin-like growth factor (I and II)(IGF), plateletderived growth factor (PDGF), fibroblast growth factor (FGF) and the bone morphogenetic
proteins (BMP’s). The mentioned factors have been isolated and some have been synthesized,
allowing for the investigation of function of the factors both alone or in combination. The
capability of isolating appropriate factors from bone, synthesizing them in large quantities, and
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reapplying them in concentrated amounts to accelerate bone healing has produced many future
possibilities for bone graft substitutes.92
While factor-based therapies have demonstrated advantages in bone defect repair and
regeneration, some distinct disadvantages remain including high manufacturing cost, risk of
contamination, potential immunological response, protein instability, 102–104 and the risk of
uncontrolled bone growth or cancer. 92,105 An alternative to factor-based therapies is the use of
‘small molecules’, which are lower-molecular-weight organic compounds than their full
protein counterparts (typically <1,000 Da). The use of small molecules is a relatively new area
of research that is growing rapidly, and their attractiveness is in part due to their capability of
diffusing across cell membranes to reach intracellular targets. 106,107

Additionally, small

molecules exhibit beneficial qualities not inherently found with protein growth factors
including being more stable, soluble, nonimmunogenic, affordable, and requiring a lower
effective dose108 while still exhibiting the same efficacy as the full protein. 92

1.4.3.3.

Cell-based

Cell-based strategies allow researchers to investigate the use of delivering exogenous
cells to a tissue defect using a suitable scaffold to accelerate tissue regeneration. Cells seeded
within a biomaterial scaffold can be cultured in vitro in bioreactors prior to implantation or by
directly seeding the cells on the scaffold before implantation. Cells have also been shown
beneficial to regenerate bone when directly injected into the defect in the absence of
biomaterials.109–111 With the emerging capabilities of regenerative medicine, various sources
of stem cells have been considered to meet patient-specific demand for bone tissue
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engineering. Stem cells are attractive candidates based on their proliferative and regenerative
capabilities hence avoiding certain supply limitations of adult somatic cells. Commonly
studied stem cells for these applications include mesenchymal stem cells (MSCs), induced
pluripotent stem cells (iPSCs) 112, and adipose-derived stem cells (ADSCs).

In 2006,

Yamanaka et al. revealed a significant breakthrough discovering how adult somatic cells
treated with the right factors could be engineered back to a pluripotent state capable of
producing any cell in the body. These cells induced back to an earlier cell lineage became
known as iPSCs and carry the potential for many regenerative capabilities. 113

1.4.3.3.1.

Mesenchymal stem cells (MSCs)

MSCs can be differentiated in vitro to the osteogenic lineage by being cultured in the
presence of certain additives including TGF-β, BMP-2, -4, and -7. Phenotypic assays and
staining can confirm the osteoblast-like cell phenotype of the stem cell. 114 MSCs have been
defined through the expression of various cluster of differentiation (CD) markers and have
been isolated from a number of adult sources including bone marrow, 115 peripheral blood,116
umbilical cord blood, 117 synovial membrane,118 adipose tissue,119 brain, skin, heart, kidneys,
and liver.120 Of common interest are bone marrow-derived mesenchymal stem cells (BMSCs),
which are multipotent stem cells capable of differentiating into several mesenchymal lineage derived cell types including osteoblasts. 121 An advantageous use of BMSCs is that they can
be obtained via bone marrow aspiration, percutaneously. Additionally, proliferation and
differentiation of stem cells derived from BMSCs can be increased by the addition of growth
factors122,123 or by seeding onto osteoconductive scaffolds prior to implantation, such as
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collagen matrices.124,125 The use BMSC-seeded scaffolds with growth factors such as BMP-2
has been shown to enhance healing of critical-size defect models in both rat 126,127 and
rabbit.128–130 While the potential regenerative capabilities of BMSCs appear vast, as with any
bone graft substitute, limitations exist. Drawbacks include the pain and discomfort from the
bone aspiration procedure and the difficulty in obtaining a sufficient number of cells required
for the procedures, particularly in the case of large bone defect repair. Additionally, studies
have shown that various factors can significantly limit the actual amount and quality of MSCs
obtainable for clinical application. Approximately four to six weeks are required for cell
expansion before clinical treatment, yet a maximum of 24-40 population doublings are reached
before the cells result in a senescence-associated growth arrest. As donor age and systemic
disease increases, osteogenic differentiation potential in vitro and bone forming efficiency in
vivo significantly decreases. Further knowledge about common markers is needed to help
identify and define MSCs isolated from different sources. 131,132

1.4.3.3.2.

Adipose-derived stem cells

ADSCs offer an attractive source of stem cells as the cells can be rapidly expanded and
as supply limitations and ease of harvesting is less problematic given the ready access of
patient adipose tissue deposits under the dermal layers. ADSCs are multipotent cells easily
isolated from fat subcutaneously that can be induced to differentiate into the osteogenic
lineage.133 Studies have shown promising results using ADSCs in animal defect models.
Implantation of poly(lactic-co-glycolic acid) (PLGA) scaffolds seeded with ADSCs in rat
calvarial defects resulted in complete healing of the defect in 3 months. 134 Successful repair
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of critical-size cranial defects in canines 135 and rabbits136 by delivery of ADSCs via coral and
nano-hydroxyapatite-collagen/PLA composites, respectively. While ADSCs do not face the
supply limitations of other cell types, drawbacks include lower osteogenic potential compared
to BMSCs, as indicated in various in vitro and in vivo studies.133 The major challenge in
finding efficacy in cellular therapies is both the identification of the cell sources as well as
appropriate scaffolds for delivery and implantation to the bone defect site in order for cellular
differentiation into osteoblasts and the formation of neo-vasculature.137,138 In addition to
MSCs, iPSCs, and ADSCs, other stem cell types including human umbilical vein endothelial
cells (HUVECs),139 muscle derived stem cells (MDSCs), 140 embryonic stem cells (ESCs),141
and endothelial progenitor cells (EPCs) 142 are also currently under investigation; however, to
date, none of these alternative cell sources have provided significant evidence to surpass the
osteogenic potential of BMSCs.

1.4.3.4.

Ceramic-based

Currently available ceramic-based bone graft substitutes include products containing
calcium sulfate, bioactive glass, and calcium phosphates. Ceramic-based bone graft substitutes
are relevant, especially calcium phosphates, because the primary inorganic compound of bone
is calcium hydroxyapatite (HA), a subset of the calcium phosphate group. As a result, the
particular manufacturing methods of calcium phosphates can come close to mimicking the
natural matrix of bones depending on the scaffold’s structure and porosity.

They are

manufactured in a variety of types including coralline HAs, synthetic HAs, and tricalcium
phosphates, which can be processed into various workable forms such as solid matrices,
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injectable pastes, or putties. Calcium phosphates exhibit relevant properties to bone graft
substitute applications as they are osteoconductive, osteointegrative, and in some cases
osteoinductive.143 It comes as no surprise that HA-based biomaterials are the most widely
used bone graft substitutes because of their unique properties.144
Studies have shown that MSCs cultured and seeded on HA constructs successfully
differentiate into osteoblasts which results in bone tissue growth on the HA surface. 145
Calcium phosphate cement (CPC) is commonly manufactured as an injectable paste and is of
particular interest. CPC is a mixture of tetracalcium phosphate and dicalcium phosphate
anhydride.146,147 The cement is unique due to its ability to react at body temperature to form a
paste containing crystals of calcium phosphates and upon implantation can form HA within
the body.146 The cement is advantageous as it is a freely moldable and adaptable material,
making it suitable for irregularly shaped bone defects.

Osteoblasts’ proliferation and

differentiation has been found to have dependence upon not only calcium phosphate
composition, but also the structure and crystallinity of the scaffold which can be modified to
particularly specifications during the fabrication process. Higher crystallinity HA has been
found to have lower efficacy for in vitro culturing of rat osteoblasts as an early increase in
proliferation was seen; however, a subsequent drop off was evident as culture time
increased.148 Lower crystallinity HA scaffolds have shown better effectiveness as cultured rat
osteoblasts experienced gradual yet increased proliferation as time increased as the scaffold
more closely mimics natural bone in overall crystallinity in comparison to highly crystalline
forms.149–151
Studies have shown a direct relationship exists between reduced crystallinity and
increased healing rates. 152 Another advantageous property of lower crystallinity calcium
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phosphates is that they are more soluble in body fluid as well as in vitro analogues in
comparison to higher crystallinity calcium phosphates, resulting in a higher ion concentration
near the scaffold,148 and a plate-like precipitation on the scaffold surface, leading to increased
bone repair activity. 153 As with any biomaterial, certain favorable biological properties have
negative tradeoffs. In particular, ceramics, including crystalline HA, are extremely brittle
resulting in failure under load-bearing situations.151,154

Additionally, the processing of

ceramics for scaffold formation often requires exposures to high temperatures which
complicates the incorporation of biological molecules. As native bone tissue demonstrates
mechanical resilience as it naturally is a composite material composed of its flexible organic
and rigid inorganic counterparts, to combat the brittle properties of ceramics, they are often
combined with other materials to form a composite for enhanced mechanical integrity.

1.4.3.5.

Polymer-based

Polymer-based solutions are considered as good candidates for bone grafting materials
due to their controllable mechanical properties and biocompatibility.

By controlling

processing, chemically modified polymer materials have the advantage to suit biological
applications through specific functionalization in addition to degradation modification. As
with any biomaterial scaffold, the polymer biomaterial must suit the mechanical demands of
the defect in addition to allowing for little to no immune response from its degradation
products.

Polymers used today can be loosely divided into two categories: natural and

synthetic polymers, which can be further divided into degradable and nondegradable.
Hydrogels are another representation of polymeric structures which consist of networks of
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natural or synthetic hydrophilic polymer chains capable of containing over 99.9% water by
mass. Hydrogels will be discussed further in the following section.
Natural polymers are derived from living sources such as animals, plants and
microorganisms. Polysaccharide-derived polymers such as chitan and chitosan, hyaluronic
acid (HA), alginate, starch and cellulose-based polymers have been on the forefront of research
for the development of scaffolds for bone, cartilage, and skin regeneration. 155 Collagen and
chitosan are two commonly used natural polymers in bone tissue engineering applications.
Collagen, a natural polymer that is vastly present in connective tissues, has been used alone or
in combination with other materials in numerous bone graft substitute applications and is a
main focus of this thesis. As collagen is a main organic component of the extracellular matrix
in bone tissue, it is highly attractive as a bone graft substitute and has been used in combination
with other materials for clinical procedures. 100 Collagen sponges, typically made from bovine
collagen, are manufactured by numerous companies with or without other growth factors
and/or materials and are commonly used in bone defect sites to promote bone growth and
healing such as in spinal fusion surgeries. 89,156–159 Medtronic (U.S.A.) manufactures a product
known as InFUSE™ Bone Graft which is a collagen sponge that serves as an osteoconductive
carrier of bone morphogenetic protein (BMP-2) for spinal fusions.160,161 Natural polymers are
advantageous for tissue engineering applications because they can mimic the endogenous
extracellular matrix and surrounding tissues recognize and metabolize their products thro ugh
common pathways. While natural polymers offer many advantages, downsides include the
possibility of causing immunological responses, lot variability among different supply sources,
and inferior mechanical properties to synthetic polymers. 92 Particularly, the compressive
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strength of collagen-based bone substitutes is typically weaker than cancellous bone, rendering
them unsuitable for load bearing bone defects. 162
Synthetic polymers a currently clinically available as options for bone grafting
materials and can be manufactured into various shapes for optimum surface textures and pore
sizes conducive to tissue formation. Degradable polymers are commonly used in tissue
engineering applications where the natural extracellular matrix will eventually replace the
scaffold. Importantly, the tissues surrounding the scaffold must be capable of processing the
degradation products from the polymer via metabolization or excretion, otherwise an
immunological response may occur.

Synthetic polymers can be designed with chemical

functional groups that allow for tissue ingrowth. Aliphatic polyesters including poly(lactic
acid) (PLA), poly(glycolic acid) (PGA), and their copolymer poly[(lactic acid)-co-(glycolic
acid)] (PLGA) are the most widely used synthetic polymers in tissue engineering and are well
characterized having gained FDA-approval for certain clinical applications such as sutures.
PLGA has been studied in multiple tissue engineering applications including bone, 163
cartilage,164 ligament/tendon,165 nerve,166 and skeletal muscle. 167 The degradation rates of
these polymers can be controlled by adjusting their molecular weights. 168 These polymers are
highly attractive due to their ease of processing and formability to suit a range of applications.
While ceramics require heating to extremely high temperatures for processing, 169
hydroxyesters have relatively low glass transition temperatures therefore being able to be
processed using conventional heating methods. 168 Specific structural and chemical properties
can be achieved by tissue engineers by methods such as solvent-casting, porogen-leaching, and
electrospinning.168
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1.4.3.6.

Hydrogels

Hydrogels are of particular interest to this work as they can be used for space-filling
scaffolds, for cell delivery, and for bioactive molecule delivery. 170 As hydrogels are another
representation of polymeric structures, they provide a great method to create a threedimensional environment for cells to migrate along their hydrophilic polymer chains in an
environment that can contain over 99.9% water by mass. A major focus of this work is the
capability to deliver an appropriate cell source to a bone defect area for remote mechanical
stimulation to accelerate bone healing and regeneration. Hydrogel-based products have been
greatly improved over recent years such as for soft contact lenses which are typical made from
poly(hydroxyethylmethacrylic) acid [poly(HEMA)]. Other biological adhesives have been
developed from reconstituted fibrin or albumin for use in surgical procedures. Applications
for hydrogels have been investigated for bone, cartilage, intervertebral, and cardiac
regeneration. Where adult muscle stem cells typically lose their pluripotency and undergo
massive cell death within the first weeks of culture on rigid plastic culture dishes, when they
were cultured on chemically crosslinked bioactive poly(ethylene glycol) (PEG) hydrogels, the
cells showed evidence of self-renewal and were engrafted with substantially better integration
in a muscle implant model. 171 Additionally, ‘smart’ hydrogels are an interesting biomaterial
currently under research for many applications due to their ability to change shapes. Smart
hydrogels are able to dynamically shrink, swell, or degrade based on exposure environmental
stimuli including pH, temperature, and other activators. As their smart capabilities allow them
to be maneuvered through small, tight pathways, they are often investigated for vascular
applications.172 Collagen hydrogels are attractive candidates for scaffolds in bone tissue
engineering and particularly for this thesis.
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1.4.3.7.

Composites

As bone tissue inherently is a composite material made of collagen proteins which
provide an elastic phase to a more rigid and stiffer calcium phosphate matrix, in order to
engineer bone graft substitutes to mimic natural and physiological conditions, in many cases,
composites, or substances containing two or more constituent materials, can best s uit the
application at hand. Where one constituent material alone could not provide the mechanical
integrity needed for an application on its own, often the combination of the two or more
materials provides the strengths of each of the materials and minimizes each constituent
material’s weaknesses. Composite-based bone graft substitutes have shown promising results
in bone tissue engineering applications. As bone is largely made of type I collagen and HA
and both materials are osteoconductive, together they can be manufactured together as a
composite material capable of supporting bone regeneration. 173

It has been shown that

collagen-HA composites provide higher osteogenic potential towards human osteoblast -like
cells in comparison to HA scaffolds alone. 174 As the use of composites can significantly
modulate the mechanical properties, the ductile properties of collagen have been shown to
increase the fracture strength of HA.

Collagen-based matrices can have their stability

significantly improved by chemical cross-linking.124,175–178 The use of aldehydes can crosslink
the amine groups within collagen; however, potentially toxic residues can remain if the process
is not appropriately optimized resulting in the implantable collagenous grafts being less
acceptable. Additionally, polymer-ceramic composites, as with bone, are capable of providing
the benefits of each material while counteracting each’s limitations. It has been shown that
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polymer-ceramic composite scaffolds have successfully been used in vitro and in vivo to
differentiate stem cells into osteoblasts. 179

1.5. Bone Tissue Engineering

Tissue engineering involves the application of biological, chemical and engineering
principles towards the development of biological substitutes for the repair, restoration, or
regeneration of tissue form and function. 24 The field of bone tissue engineering investigates
the combination of interaction of cells with specific biomaterials and/or growth factors to
restore bone to its original and functional state following instances of fractures, trauma, or

Figure 9. Tissue engineering paradigm. Cells are isolated from donor/source, seeded in
combination with appropriate growth factors onto the biomaterial scaffold, and the
construct is implanted into the host defect site.180
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extraction of tissue due to diseased states. The tissue engineering paradigm can be seen in
figure 9 displaying the three main components for tissue regeneration: the biomaterial scaffold
that serves as a substrate onto which cells and biological molecules can reside; the growth
factors or small molecules that function to influence cellular behavior; and the patient-specific
cells responsible for building the tissue. 180 The design of a scaffold should involve the
consideration of the following critical criteria: 1) suitable biomaterials should be s elected in
regards to both the tissue type to be replaced and the degradation time to match the ingrowth
of newly forming tissue; 2) appropriate initial mechanical strength and stiffness to substitute
for the mechanical function of the defect area where the damaged tissue is to be
repaired/regenerated; 3) optimization of the scaffold surface to encourage cell attachment,
proliferation, differentiation, and migration through the scaffold; 4) minimal to no immune
response, neither from the initial intact biomaterial nor its degradation by-products; 5)
interconnected pore structure so that both cell migration and proliferation in initial stages and
consequently ECM infiltration for the desired tissue is supported without compromise of
mechanical integrity; and, 6) the scaffold should be reproducible at an economic cost and
reasonable efficacy. 180 Critical sized bone defects are incapable of healing on their own due
to the size of the defect and the difficulty in cell migration to effectively fill the void. When
choosing appropriate and effective bone tissue engineering experiments, one must consider the
location and mechanics of the bone in need of being regenerated. For example, cortical bone
and trabecular bone each have different storage moduli. If an implant is chosen that is too
strong for the defect, commonly seen with metal biomaterials, a phenomenon known as stress
shielding181–183 can occur where the implant or scaffold is taking on the load of the typical
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weight bearing area of the native tissue, ultimately causing it to not heal properly due to the
lack of stresses the bone cells need to build and remodel their tissue.
Researchers factor in the desired properties of an optimal biomaterial as discussed in
the bone graft substitutes section when designing and fabricating scaffolds for bone tissue
engineering applications.
biodegradability

or

To reiterate, the properties included mechanical properties,

bioresorbability,

biocompatibility,

porosity,

osteoconductivity,

osteointegrity, osteoinductivity, and osteogenicity. To achieve optimal levels for cellular
attachment, growth, proliferation, migration, etc. as well as incorporation into host tissues,
scaffolds are designed with optimal materials and fabrication techniques. Particularly, the
scaffold structure including topographical features at both the micro and nano scale is a
promising approach to control the cellular function towards tissue engineering applications.
In particular with native bone tissue, bone cells live within the ECM containi ng an array of
organized nanofibers where this structure acts as a support system that can guide cellular
functions including proliferation, differentiation, adhesion, and migration by way of physical
cues.184 Therefore, evidence has shown that scaffold topography alone, independent of the
substrate chemistry, may have various modulatory effects on cellular functions. 185 By using
various fabrication methods, unique micro and nano topographies have been created to
evaluate how topography effects cellular functions. 186 Evidently, topographical cues have
been correlated with cell shape, alignment, migration, and proliferation. 187 Additionally,
nanotopography has been shown to be a regulator of microRNA expression, gene expressi on,
and cellular differentiation. 188
Considering the vast array of parameters in tissue engineering applications studies
including differences in cell sources, the materials used in scaffold fabrication, fabrication
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methods resulting in size and shape differences, environmental conditions such as growth
media and study time points, establishing a consensus on how specific cell types respond to
scaffold topography has been found difficult. Many fabrication techniques are used to aid in
the formation of biomimetic scaffold structures.

Biomimetics refers to human-made

substances, devices, processes or systems that imitate nature to solve complex human
problems. As species and their systems have evolved in nature over thousands or more years,
many of nature’s technology can be harnessed to solve complex problems in engineering and
in particular the field of medicine, so in essence ‘reinventing the wheel’ can be avoided for
efficiency in resources – mainly time and funding as both are very costly in research. In
summary, when designing a tissue engineering scaffold, researchers must consider the
physical, chemical, and biological properties of the biomaterial scaffold in respect to the graft’s
potential ability to facilitate the initial and prolonged functional tissue growth.

1.5.1. Cell-based Strategies

The use of cell-based treatments for bone repair and regeneration were discussed
previously in detail in the bone graft substitutes section. Stem cell types including MSCs,
iPSCs, ADSCs, MDSCs, HUVECs, ESCs, and EPCs are some of the many cell sources
commonly investigated for bone tissue engineering applications.

To reiterate, the

implementation and delivery of cells to a defect whether it be for bone tissue engineering or
other tissue engineering applications, must involve a delivery system to localize and maintain
cell viability for functional tissue regeneration and growth, which is a main focus of this work.
While it appears intuitive that large scale tissue defects require a support matrix to maintain
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cells locally within the defect, other applications using a direct injection of cellular suspension
have gained common interest lately for treatment of degenerative chondral lesions and
osteoarthritis within joints. Platelet-rich plasma (PRP) therapy alone or in combination with
MSC therapy have been used clinically as intra-articular injections for degenerative
osteoarthritis (OA) for patellofemoral joint (PTF) degeneration and in other joints as well.
PRP therapy has shown efficacy in treating pain and improving functionality in joints with
cartilage lesions or OA, 189–191 as well as evidenced in diagnostic imaging of cartilage integrity
using magnetic resonance imaging (MRI). 192 Additionally, PRP therapy efficacy has been
seen in the treatment of other tendon and ligament disorders including tendonitis 193 and
anterior cruciate ligament (ACL) 194 injury.

1.5.2. Scaffolds for Bone Regenerative Engineering Strategies

1.5.2.1.

Electrospinning

Electrospinning is a method to create scaffolds that uses and electrical field to control
the formation and deposition of polymer and/or composite fibers on a target surface. 195 Figure
10 illustrates a schematic of a typical electrospinning setup.

Electrospinning works by

charging a droplet of polymer solution pumped at an appropriate rate out of a needle and
syringe. The droplet of polymer gets charged through a high voltage source which is connected
to the metal needle, and the droplet will elongate to form a Taylor cone. When the solution
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A

B

Figure 10. Schematic representation of an electrospinning setup with high voltage applied
to polymeric solution sprayed on to a grounded collector (A). Polymeric nanofibers under
SEM microscopy.195

reaches the optimal voltage, a fibrous jet emerges from the Taylor cone and is attracted to the
grounded collector, which is commonly a flat piece of aluminum metal due to its conductive
properties. While the jet initially follows a straight path, the bending instability of the
electrified polymer leads to a whipping motion, during which electrical forces cause the jet
stream to stretch and thin. 195,196,197 As the solvent evaporates, micro or nanofibers will be
formed from the jet and are pulled toward the grounded collector where they form a nonwoven
mat. Various parameters can affect the formation of fibers and can be adjusted depending on
the desired properties of the scaffold to be manufactured. Parameters include humidity,
voltage applied, polymer charge, polymer solution viscosity, and distance between the needle
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tip to the grounded collector. When parameters are not optimal for a given setup, nanofibers
will not develop resulting in electrospraying rather than electrospinning an d fiber deposition.
Electrospun nanofibers are an attractive biomaterial scaffold as their nanoscale
diameter and high surface area-to-volume ratio offer biomimetic properties, which are similar
to the natural cellular ECM. Electrospinning is a fairly simple and affordable method for
scaffold design and allows for the use of biodegradable polymers and materials which
ultimately allow for scaffold incorporation into host tissues as well as controlled release of
various loaded bioactive molecules, such as small molecules, proteins, drugs, DNA, or
RNA.198,199 A large variety of polymers are feasible for use in electrospinning and the
production of nanofibers as they are well documented in literature. 200 Some of these polymers
include natural polymers such as chitosan 201, gelatin199, and collagen 202; while synthetic
polymers have been successfully manufactured into nanofibers such as poly (epsilon caprolactone) (PCL) 203, poly (lactic-co-glycolic acid)204, and poly (lactic acid) 205 which are
commonly used for regenerative applications.

1.5.2.2.

Microspheres

Microspheres are readily made by an emulsion solvent extraction/evaporation
method.206,207 This is achieved by emulsifying a polymer solution in a non-solvent containing
stabilizer. PLGA, a commonly used polymer in biomedical applications, can be dissolved in
a solvent such as methylene chloride, and emulsified in an aqueous solution containing poly
vinyl alcohol, which serves as the stabilizer. The emulsion process is commonly prepa red by
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either stirring or sonication of the two solutions. Once the polymer solution is emulsified, the
organic solvent is given time to evaporate to form solid microparticles.
Microspheres in biomedical applications are commonly used as an injectable system
for controlled drug delivery or can be sintered, a heating process to make the microspheres
coalesce into a porous mass, under various conditions to fabricate three-dimensional matrices
for tissue engineering applications. 208,209 Various methods can be used to sinter microspheres
into a three-dimensional scaffold including heat sintering, solvent/non-solvent sintering, as
well as solvent vapor treatment. 210–213 The release of molecules from microspheres can be
controlled by several factors including the molecular weight of the polymer used. 211 Sintered
scaffolds have been used as drug, protein, and peptide delivery vehicles, as well as for gene
therapy.214–216 Advantages of using sintered microsphere scaffolds include ease of fabrication,
control over morphology, pore interconnectivity, and the ability to control the releas e of
various encapsulated bioactive molecules leading to the facilitation of cellular infiltration and
migration into the scaffold from host tissue.208,217,218

1.6. Ultrasound Theory

1.6.1. Physics of Sound

There were multiple important historical findings that lead to the understanding of
sound and the discovery of ultrasound. Dating back the furthest, Sir Isaac Newton first
proposed his theory that sound is a wave in 1687.219 About two hundred years later in 1877,
Lord Rayleigh discussed the field of modern acoustics.220 As one of the last key findings in
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1880, the Curie brothers discovered the piezoelectric effect 221 which ultimately led Paul
Langevin to develop one of the first uses of underwater ultrasound at a frequency of about 150
kHz.222 In general terms, sound can be described as a mechanical wave that moves through a
medium such as gases, liquids, or solids. The wave travels at a particular velocity depending
on the density and temperature of the medium. For example, at room temperature, sound
travels through water around 1500 meters per second. A common parameter of sound is
frequency, which is the amount of cycles per second. Humans can hear a particular range of
frequencies. The ‘ultra’ in ultrasound is termed so because it is at a higher frequency beyond
the limits of human hearing which is approximately at 20 kHz or higher. 223–226

1.6.2. Bioeffects of Ultrasound

This section discusses the noncavitational, nonthermal bioeffects of ultrasound. These
bioeffects are produced in the absence of cavitation bubbles or other gas bodies in the exposed
sample. There are three main mechanisms of action: acoustic radiation force; radiation torque
or acoustic streaming.

Ultrasound beams in fluid media have also been shown to be

accompanied by acoustic streaming, or time averaged velocity (i.e. fluid flow in or surrounding
the beam and generally moving in the direction of beam propagation). 227 Acoustic radiation
force (ARF), or acoustic pressure, occurs when a body is irradiated by an ultrasonic beam
resulting in an experienced force. It is defined as a steady force caused by radiation. 228 The
radiation force was first measured in 1903. 229,230 The force that is experienced is dependent
upon the intensity of the source, the beam field, and the physical properties of the body being
irradiated.231 For this particular study, radiation force occurs when biological tissue responds
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to a force by moving in the direction of the incident sound wave. Acoustic radiation force has
the ability to deform the biological tissue or set it in motion. 228 Tissues with low physical
strength may lose their structural integrity if the force is great enough to cause the tissue to
tear or be disrupted. If the wave comes into contact with an object that absorbs the energy
completely, then a force is imparted upon the object. This occurs because a traveling acoustic
wave carries energy and momentum from its source. Measuring this force is a common method
for quantifying the output of clinical ultrasound. 230,232–234 Additionally, Torr showed that the
observed force is the result of “the transfer of wave momentum”.229 We hypothesize that the
beneficial bone healing effects of ultrasound results from the mechanical load the ultrasound
imparts on the cells and extra-cellular matrix.

1.6.3. Mechanotransduction

All living organisms experience mechanical forces, from the cellular level all the way
to the organism’s entire structure as a whole. Forces take part in occurrences at molecularand cellular-level structures in all tissues in a phenomenon coined as mechanotransduction,
where bone tissue is of no exception and is researched greatly. 235–241 As this thesis is centered
around bone tissue engineering and the link of acoustic radiation force via ultrasound and its
efficacy, mechanotransduction is of great interest, which has been defined as the “process of
converting physical forces into biochemical signals and integrating these signals into the
cellular responses”.242 Mechanotransduction commonly involves a series of discrete steps
which lead to the general objective of growth. 243
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Examples of mechanotransduction in the body at various tissue levels have been well
cited in literature. Osteoblast proliferation and increased matrix deposition has been evidenced
from mechanical stimulation of the skeleton by exercise. 244 Exercise also has been shown to
stimulate chondrocyte proliferation and increase cartilage synthesis. 245

Increases in

mechanical pressure in the heart results in compensatory fibroblast proliferation and
cardiomyocyte hypertrophy. 246

However, when mechanosensitive tissues experience the

absence of mechanical stimulation, tissue degradation results. 243

Immobilization or

microgravity leads to acute, rapid, and severe bone loss in humans and animals, 247 and disuse
of a limb leads selectively to bone degradation in that limb 248 which is due to the lack of
stimulation of the osteocyte, the key mechanosensitive cell. 243 Furthermore, the significance
of mechanotransduction in bone is evidenced clearly during spaceflight as reduction in bone
formation,249 mineral content,250 and bone matrix protein production 251 result from skeletal
unweighting.
While mechanotransduction is known to play a crucial role in the physiology of many
tissues, the process of mechanotransduction of bone can be divided into four stages: 1)
mechanocoupling; 2) biochemical coupling; 3) transmission of signal; and 4) effector cell
response.241 Mechanocoupling refers to the physical transduction of mechanical energy in a
manner that it can be detected by cells. An example of this in animals is where bones of the
middle ear transduce sound waves in air into stress waves within fluid of the cochlea.
Additionally, the mechanical loads in vivo in bone cause deformations that result in the
stretching of bone cells within and lining the bone matrix resulting in fluid movement within
the canaliculae of bone. The phenomenon of dynamic loading causes extracellular fluid flow
and creates streaming potentials within bone and is most effective for stimulating new bone
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formation in vivo.252,253 Bone cells in vitro exposed to fluid flow or mechanical stretch are
stimulated to produce secondary messangers. 254
Biochemical coupling is the coupling of cell-level mechanical signals into intracellular
biochemical signals. Possible mechanisms for these include force transduction through the
integrin-cytoskeleton-nuclear matrix structure, stretch-activated cation channels within the cell
membrane, G protein-dependent pathways, and linkage between the cytoskeleton and the
phospholipase C or phospholipase A pathways. 241 It is theorized that the entire cell is a
mechanosensor based on the tight interaction of each of these pathways and that there are
numerous pathways available for the transduction of a mechanical signal. 241 The third distinct
step in the process of mechanotransduction is the transmission of signal where osteoblas ts,
osteocytes, and bone lining cells may act as sensors of mechanical signals subsequently to
communicate the signal through cell processes connected by gap junctions. 241 These bone
cells can produce paracrine factors to cause osteoprogenitors to differentiate into osteoblasts
and attach to the bone surface. Additionally, insulin-like growth factors and prostaglandins
are studied as intermediaries in signal transduction. 255,256 In the final step of the process of
mechanotransduction, the effector cell response exhibits the effects of mechanical loading as
expressed by the magnitude, duration, and rate of applied load. As with the calculus theory
and the notion of the area under the curve, the same effect on bone formation is seen with
longer duration and lower amplitude loading in comparison to short duration and higher
amplitude loading.241,257 In order for the stimulation of new bone formation, loading must be
cyclic; however, aging greatly reduces the osteogenic effects of mechanical loading, and
hormones can affect the sensitivity of the sensor or effector cells to mechanical loads via
interaction with local mechanical signals. 241
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Figure 11. The four mechanical usage windows defined by mechanostat theory (adapted
from Burr and Martin). 268

As discussed previously, bone mass and architecture is controlled in part by adaptive
mechanisms sensitive to their mechanical environment. The theory that mechanical forces
shaped the architecture of the skeleton emerged in the 19 th century in the works of Roux 258 and
Meyer.259 However, literature’s most famous ties with bone adaptation theory is seemingly
always tied with Julius Wolff. 260 Considering Meyer’s observations concerning cancellous
bone structure, Wolff proposed that the architecture of bone was indicative upon its mechanical
stress. Furthermore, Wolff expressed that the form of bone is related to mechanical stress by
a mathematical law known as Wolff’s law of bone formation. 260 While today it is known today
that some tenets of Wolff’s law are incorrect, 261 the basic principles that mechanical forces
affect the form of bone still remains largely accepted. 262,263 A more recent interpretation of
Wolff’s law proposed by Frost suggests that changes in bone structure are caused by a feedback
system where changes in local mechanical signals trigger bone cells to change bone structure.
Frost’s “mechanostat” theory presents a distinction between modeling and remodeling
processes and thresholds for activating lamellar or woven bone formation in which there is a
window of mechanical usage that should be considered normal or physiological (figure
11).262,264–268 If bone tissue experiences mechanical forces exceeding the upper boundary of
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the physiological window, known as the minimum effective strain (MES), bone undergoes
modeling, or sculpting, where its structure is changed to reduce local strains to a level below
the MES.241 Additionally, when forces on bone tissue are very large resulting in bone strains
pushed into a pathological overload zone, woven bone formation will occur on bone surfaces.
However, on the other end of the spectrum when forces are low enough producing a lower
MES, bone tissue will be resorbed until the local strains are increased. 241 While mechanical
forces resulting in strains on bone tissue is a main driving factor to bone formation/resorption,
Frost suggested that various hormones and biochemical signals can alter the mechanostat
phenomenon of bone thus altering the boundaries of the physiological window allowing normal
mechanical usage to significantly increase bone mass and bone strength. 265 Much of this work
focuses on certain mechanosensory pathways with preosteoblasts as mechanotransduction is a
hypothesized bioeffect phenomenon from the stimulation of LIPUS via acoustic radiation
force. Further discussion of this notion is discussed in the following sections.

1.6.4. Medical Ultrasound

In medical ultrasound equipment, a transducer consisting of a piezoelectric crystal
converts a particular ultrasound frequency (1-12 MHz) as an electrical signal into a mechanical
vibration resulting in acoustic energy. As the human body consists of a high percentage of
water, this acoustic energy produced by the transducer can be used as a minimally invasive
technique to propagate through the skin and various tissues at different impedances. 269
Medical ultrasound devices range in their functions and uses, such as surgical applications,
diagnostics, for example imaging, and therapeutics for cancer treatment, kidney stones via
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ablation, tissue swelling in physical therapy, and fracture healing. 270,271 Seemingly the most
critical factor in medical ultrasound is the measurement of the acoustic energy output which
leads to the key parameters: intensity and spatial intensity. Intensity refers to the total power
output of a device (typically measured in Watts) while spatial intensity may be a more useful
term in medical therapies as it indicates the device’s power output normalized to a particular
area (commonly measured in Watts/cm 2).272–275 To refresh, power indicates energy per unit
time. Ultrasound devices may be engineered at higher or lower intensities – whatever is
optimal for the given treatment or diagnostic testing. Medical ultrasound units can have output
intensities range from milliwatts all the way to 1,000 watts or more depending on their
application. If compared to household appliances as a way to put the output intensities into
perspective, medical ultrasound devices have somewhat similar output when taking the
example of two common household devices: a 5 watt LED lightbulb and a 1,000 watt
microwave. While the 5 watt LED lightbulb barely produces any heat, it is still a few orders
of magnitude higher than some types of medical ultrasound devices such as low intensity
pulsed ultrasound, the therapeutic device for fracture healing, which operates at a spat ial
intensity of only 30 mW/cm 2 and will be discussed further in the following section and is the
focus of this research. However, as the 1,000 watt microwave uses a lot of power, it is capable
of producing high amounts of heat in a short period of time as its intended purpose is to cook
or heat food rapidly. The high wattage microwave power output is similar to the high end of
the spectrum of medical ultrasound, such as high intensity focused ultrasound (HIFU) which
is used for thermal ablation of tissues where HIFU systems have been shown to operate in the
100s to 1,000s Watts of total output and 1,000s to 10,000s Watts/cm 2 of spatial intensity
resulting in tissue temperature increases up to 100°C.276,277
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1.6.5. Ultrasound for Fracture Healing (LIPUS)

1.6.5.1.

History and Background

In the mid-1990s the U.S. Food and Drug Administration (FDA) approved the use of
low intensity pulsed ultrasound (LIPUS) devices for therapeutic applications, specifically for
fresh fractures in 1994 and for non-union fractures in 2000.269 Clinical evidence has shown
the beneficial effects of LIPUS as fresh fracture healing time is reduced by 38% 278 and nonunion defects heal at an 85% success rate.279 While the use of LIPUS has proven beneficial in
bone repair, the exact mechanism behind its success still remains unclear.

Further

investigation into LIPUS parameters as well as cellular and environmental effects may provide
insight into this phenomenon, as is a major theme of this thesis.
As the name implies, LIPUS is an acronym for low intensity ultrasound, as opposed to
high intensity ultrasound used in other medical applications (see Medical Ultrasound).
Clinically, LIPUS is applied transdermally over the fracture site for twenty minute daily
treatments for the duration of the fracture healing time determined by the clinician. Given that
the LIPUS treatment was to be applied over one area for a substantial duration of time without
considerable heating or other damaging effects, the FDA set a spatial intensity of 30 mW/cm 2
of which the devices must not exceed, which is orders of magnitude lower than high intensity
focused ultrasound (HIFU). 280 The low spatial intensity was determined by the FDA in part
so that local tissue heating would not exceed 1 °C.
As a therapeutic ultrasound device is essentially an electromechanical device, general
knowledge of electrical engineering principles, particularly in signals, is necessary to

63

understand the basics of the system – how an electrical signal (waveform) is converted into a
mechanical impulse via a transducer as a medical therapy for fracture healing. The following
parameters are essential in the understanding and engineering of an ultrasound system: 281–283

AMPERE - A unit of measure for the flow of current in a circuit. One ampere is the amount of
current flow provided when one volt of electrical pressure is applied against one
ohm of resistance.
AMPLIFIER - A device of electronic components used to increase power, voltage, or current
of a signal.
AMPLITUDE - A term used to describe the maximum value of a pulse or wave. It is the crest
value measured from zero.
BURST MODE - The function generator generates N cycles of a waveform every t seconds.
BURST WIDTH - The length of time a signal is burst as it goes through N cycles. Also known
as pulse width.
CALIBRATION - The determination or rectification of the graduations used on a testing
instrument.
CARRIER SIGNAL - The base waveform that is used to pulse durations of the signal during
burst mode.
CURRENT - The flow of electric charge such as in an electric circuit this charge is carried by
moving electrons in a wire. The SI unit for measuring an electric current is the
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ampere, which is the flow of electric charge across a surface at the rate of one
coulomb per second.
CYCLE - The change in an alternating electrical sine wave from zero to a positive peak to zero
to a negative peak and back to zero.
DUTY CYCLE - The ratio of time a load or circuit is ON compared to the time the load or
circuit is OFF. Duty cycle, sometimes called “duty factor,” is expressed as a
percentage of ON time.
ENERGY - The property that must be transferred to an object to do work. The SI unit for
energy is the joule (J), where 1 joule is equal to 1 newton-meter.
FREQUENCY - The number of pulse or wave cycles that are completed in one second
(measured in Hertz). Frequency is equal to the inverse of the period.
FUNCTION GENERATOR - Electronic test equipment or software used to generate different
types of electrical waveforms over a wide range of frequencies. Some of the
most common waveforms produced by the function generator are the sine,
square, triangular and sawtooth shapes.
HYDROPHONE - A microphone designed to be used underwater for recording or listening to
underwater sound. Most hydrophones are based on a piezoelectric transducer
that generates electricity when subjected to a pressure change. Such
piezoelectric materials, or transducers, can convert a sound signal into an
electrical signal since sound is a pressure wave.
INTENSITY - The power output of a device.
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OHM - The standard unit for measuring resistance to flow of an electrical current. Every
electrical conductor offers resistance to the flow of current, just as a tube
through which water flows offers resistance to the current of water. One ohm is
the amount of resistance that limits current flow to one ampere in a circuit with
one volt of electrical pressure.
OSCILLOSCOPE - A type of electronic test instrument that allows observation of constantly
varying signal voltages, usually as a two-dimensional plot of one or more signals
as a function of time. Other signals (such as sound or vibration) can be converted
to voltages and displayed.
PERIOD - This is the length of time in seconds that the waveform takes to repeat itself from
start to finish. The period is equal to the inverse of the frequency.
POWER - The energy per unit time, commonly measured in watts.
PIEZO ELECTRIC DEVICE - A device made of crystalline materials, such as quartz, which
bend or distort when force or pressure is exerted on them. This pressure forces
the electrons to move.
PULSE - A signal that is produced by a sudden ON and OFF of direct current (DC) within a
circuit.
PULSE REPETITION FREQUENCY - The frequency at which the carrier signal is repeated
or burst. Also, this parameter may be referred to as pulse rate or signal repetition
frequency.
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RESISTANCE - The opposing or retarding force offered by a circuit or component of a circuit
to the passage of electrical current through it. Resistance is measured in ohms.
SPATIAL INTENSITY - The power output normalized to an area. For LIPUS applications
the units are commonly mW/cm 2.
VOLTAGE - That force which is generated to cause current to flow in an electrical circuit. It
is also referred to as electromotive force or electrical potential. Voltage is
measured in volts.
WATT - A unit of measure for indicating the electrical power applied in a circuit. It is obtained
by multiplying the current (in amperes) by the electrical pressure (in volts)
which cause it to flow. That is: watts = amperes x volts. 1 watt is equal to 1
joule per second.
WAVE - A signal that is produced by varying a continuous flow of current within a circuit.
Waveforms can be created by either AC or DC current.
WAVEFORM - A graphical representation of electrical cycles which shows the amount of
variation in amplitude over some period of time.
LIPUS is typically applied by using a low amplitude 1 or 1.5 MHz sinusoidal carrier
wave to meet the appropriate spatial intensity and pulsed at 1 kHz (pulse repetition frequency
or PRF) at regular intervals (20% duty cycle) as opposed to a continuous wave. Figure 12
shows the typical LIPUS waveform. To better explain the signal parameters, every millisecond
(the inverse of the PRF), a 1 MHz frequency signal is turned on for 200 microseconds and then
turned off for 800 microseconds. The ratio of time that this 1 MHz carrier wave is on (200
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Figure 12. Drawing of a typical LIPUS waveform signal used in fracture healing therapy.

microseconds) over the total time period that it pulses at (1 millisecond or 1,000 microseconds)
is termed the duty cycle and equates to 20% as noted above. A signal that is pulsed at the same
rate (1 millisecond) but is kept on for 500 microseconds and off for the remaining 500
microseconds of the period, intuitively equates to a 50% duty cycle. A signal that remai ns on
all of the time is continuous, resulting in a 100% duty cycle.

1.6.5.2.

LIPUS in vitro and in vivo studies

While the use of LIPUS therapy for fracture healing has been studied extensively over the
last couple of decades, researchers still remain unclear on a biological mechanism leading to its
efficacy. This section summarizes some of the well-cited studies. One theory behind LIPUS
therapy efficacy suggests that LIPUS induces greater blood flow at the defect site resulting in
promoting better in vivo healing, but various in vitro studies have shown that LIPUS is responsible
for further actions and various biochemical signal responses. To name a few, LIPUS has been
shown to increase osteoblast production of vascular endothelial growth factor and fibroblast
growth factor,284 promote chondrocyte aggrecan and type II procollagen synthesis,285 inhibits
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osteoclastogenesis,286 stimulates PGE2 and COX-2 expression,287 and elevates intracellular
calcium,285 osteocalcin, and gene expression for alkaline phosphatase, TGF-β, osteopontin, and
BMP-7.269,288 With all of this taken into consideration, no definitive mechanism behind LIPUS’
clinical efficacy has been identified. For ease of display, some of the well-cited in vitro and in
vivo LIPUS studies are listed below in table 3.269

Animal Model
or Cell Type

Treatment

Outcome

In vivo

Rat tibial
nonunion animal
model

Low-intensity pulsed
ultrasound 20 min/day
for 2, 4, and 6 wk

Warden et al.
(2006)

In vivo

Rat femoral
fracture animal
model

Low-intensity pulsed
ultrasound 20 min/day
for 5 days/wk

13.3% of nonunions
healed after 2 wk;
31%, after 4 wk; 50%,
after 6 wk
17% increase in bone
mineral density after
40 days of treatment

Li et al.
(2007)

In vivo

Rat ulnar stress
fracture animal
model

Low-intensity pulsed
ultrasound 20 min/day
for 5 days/wk

Rawool et al.
(2003)

In vivo

Dog ulnar fracture
animal model

Low-intensity pulsed
ultrasound 20 min/day
for 1 wk

Takayama et
al. (2007)

In vitro

Osteoblast
proliferation and
differentiation

Low-intensity pulsed
ultrasound 20 min/day
for varied durations

Sena et al.
(2005)

In vitro

Rat marrow
stromal cell gene
expression

Low-intensity pulsed
ultrasound for 3 hr

Sant’Anna et
al. (2005)

In vitro

Study

Study Type

Takikawa et
al. (2001)

Low-intensity pulsed
ultrasound for 20
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Peak in bone
formation after 4 wk
but increases at 8 wk
as well compared
with untreated limbs
Threefold increase in
blood flow around
fracture site
Increased expression
of alkaline
phosphatase, Runx2,
Msx2, Dlx5, Osterix,
bone sialoprotein,
mineralized nodule
formation, and
calcium content
within nodules
Increased gene
expression of c-jun,
c-myc, COX-2, Egr-1,
TSC-22, osteonectin,
and osteopontin
Increased gene
expression of Cbfa-

Rat marrow
stromal cell gene
expression

min/day for 1, 3, 5, and
7 days

1/Runx-2, insulin-like
growth factor,
alkaline phosphatase,
osteopontin,
transforming growth
factor-β, and BMP-7

Reher et al.
(2002)

In vitro

Human
mandibular
osteoblast protein
expression

Ultrasound of varied
intensities for 1, 2, 4, 6,
8, 12, 18, and 24 hr

Increased expression
of prostaglandin E2
and nitric oxide

Parvizi et al.
(2002)

In vitro

Rat chondrocytes

Low-intensity pulsed
ultrasound for 2 sec
through 10 min each
day for 3 days

Increase in
intracellular Ca2+

Li et al.
(2006)

In vitro

Rat calvarial cells

Low-intensity pulsed
ultrasound for 15 min

Increase in
intracellular Ca2+

Yang et al.
(2005)

In vitro

Mouse osteoblast
cells

Increase in α2, α5,
and β1 subunits

Tang et al.
(2006)

In vitro

Mouse osteoblast
cells

Low-intensity pulsed
ultrasound for 10
min/day with varied
intensity
Low-intensity pulsed
ultrasound for 20
min/day

Increase in α2, α5,
β1, and β3 subunits
and phosphorylation
of focal adhesion
kinase

Table 3. In Vivo and In Vitro Studies Evaluating the Effectiveness and Mechanism Behind
Low-Intensity Pulsed Ultrasound Treatment for Bone Repair269
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2. PROJECT OVERVIEW AND SPECIFIC AIMS

2.1. Project Overview and Specific Aims

The goal of this thesis was to find more conclusive evidence as to how LIPUS is effective
at bone healing in addition to optimizing the currently used clinical therapy. We developed and
characterized our own highly tunable ultrasound system as well as a hydrogel scaffold system for
tissue mimetics. A series of experiments evaluated the response of our adjustable ultrasound
system to: cells alone; hydrogels alone; cell-hydrogel encapsulation; and cell-hydrogel
encapsulation implantation into a mouse calvarial model. We hypothesized that LIPUS imparts a
physical load via acoustic radiation force on cells and results in a mechanical deformation of the
construct it acts on. Additionally, the use of collagen hydrogels with encapsulated cells implanted
into a defect site such as in a mouse calvarial defect model, would result in enhanced healing with
the remote mechanical stimulus of LIPUS treatment in comparison to groups without treatment.
The study is organized into specific aims as detailed below.

Specific Aim I: To characterize a tunable ultrasound system and collagen type I hydrogel
scaffold system.
It his hypothesized that acoustic radiation force and hence spatial intensity is directly
proportional to amplitude and duty cycle and hydrogel deformation. Furthermore, it is
hypothesized that hydrogel storage modulus is directly proportional to hydrogel collagen
concentration. A hydrophone will be used to calibrate the ultrasound system’s output,
and a rheometer will test the viscosity of the hydrogels based on their collagen
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concentration constructed at a range of optimal working viscosities.

Encapsulated

fluorescent beads will be tracked at four different collagen concentrations via imaging
before, during, and after ultrasound treatment at the clinical parameters as well as ot her
duty cycles and intensity.

Specific Aim II: To evaluate the effect of LIPUS in vitro.
It is hypothesized that the clinical LIPUS treatment will enhance certain osteogenic
expression of MC3T3 cells. Furthermore, it is hypothesized that mechanosensory marker
COX-2 expression will be dependent upon LIPUS treatment and intensity. Ultrasound
treatment will be administered to MC3T3 cells cultured on TCP and encapsulated in three
different concentrations of collagen hydrogels. RT-PCR analysis will be performed for
up to 21 day time points for osteogenic markers and short term time points for COX-2
expression.

Specific Aim III: To evaluate in vivo effects of LIPUS in a critical sized defect combined
with an implantable collagen hydrogel.
It is hypothesized that the combined treatment of LIPUS with an injectable BMSCencapsulated collagen hydrogel will provide enhanced healing in a mouse calvarial defect
model in comparison to no LIPUS treatment. Samples will be evaluated with x-ray
imaging, and histological analysis will be performed on samples to evaluate the extent of
donor cell survival, new bone formation, mineralization, and remodeling.
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2.2. Preliminary Data

2.2.1. Ultrasound System Setup

In order to be able to run ultrasound experiments, an ultrasound system was designed
and setup on a wheeled cart for portability. As commercially available clinical ultrasound
devices to treat fractures and fracture non-unions are limited to only one output parameter
(such as the Exogen unit from Smith and Nephew), the system was designed to have a high
degree of control and verification over system output parameters. Preliminary studies verified
the output parameters of the equipment and their relevance to clinical medicine. The waveform
signal was produced by an Agilent 33210A 10 MHz waveform generator (Agilent
Technologies, Santa Clara, CA). The signal was amplified to a desired output level by using
an ENI 403LA Broadband Power Amplifier (37dB, .15-300MHz, 1V Max) (Manufacturer,
City State), which was subsequently sent to a 1 MHz unfocused immersion transducer with a
0.75” nominal element size (Olympus NDT, Inc. Waltham MA) to generate ultrasound. The
clinically relevant output and calibration of the transducer was performed by selecting
appropriate parameters from the waveform generator: carrier frequency, pulse repetition
frequency, duty cycle, and amplitude. The portability of the ultrasound system allowed for
convenience and efficiency when calibrating various ultrasound transducers on the bench top,
performing cell studies in the culture hood, and transporting the system for in vivo studies.
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2.2.1.1.

Heating Effects

Figure 13. A schematic of the temperature testing setup with an ultrasound transducer
and thermocouple submerged in DI water.

One possible concern of ultrasound treatment on healthy tissue is excessive heating;
however, a small amount of heating could be beneficial and promote blood flow. Higher
intensity ultrasound can raise temperatures considerably (Medical Ultrasound). Give n both
scenarios, local temperature was monitored to answer two questions: 1) does LIPUS raise local
temperatures significantly enough to result in harm to cells for in vitro experiments; and 2) can
local heating be responsible for effects seen during testing.
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Important to note is that the FDA mandates that local temperatures for LIPUS treatment
not increase by more than 1°C. An initial experiment was run to apply ultrasound at different
intensities (amplitudes) to water in six-well plates incubated at 37°C to provide a baseline for
various ultrasound intensities. To reproduce the parameters of the clinical LIPUS settings, the
waveform generator was set to produce a 1 MHz signal with a 20% duty cycle and a 1 kHz

Thermal Effects of 1 MHz Pulsed Sine Wave with 1 kHz Pulse
Repetition Frequency and 20% Duty Cycle
50 mV

100 mV

150 mV

200 mV

Temperature Increase (°C)

1.4
1.2
1
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0.6
0.4
0.2
0
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10

15

20
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Figure 14. Temperature increase from ultrasound exposure at various amplitudes over 5,
10, 15, and 20 minutes.

pulse repetition frequency. The setup consisted of 6-well plates filled with DI water which
were allowed to equilibrate at 37°C overnight. Next, the transducer was submerged into a well
and run with the specified parameters at amplitudes of 50, 100, 150, and 200 mV for 20
minutes. The temperature of the water was measured in each well at the start of each run and
then at 5 minute intervals for the duration of exposure. A schematic of the setup can be seen
in Figure 13. Temperature change is plotted in Figure 14. Importantly, all sets of parameters
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except for 200 mV after 15 minutes did not result in a temperature increase of greater than
1°C, therefore verifying the FDA mandated limit for local heating by an ultrasound device was
not exceeded. Additionally, even at the most extreme conditions tested, the temperature rise
barely exceeded 1.25°C after 20 minutes of exposure to an intensity greater than currently used
clinically for LIPUS devices. Also, these conditions were tested in a static well of fluid which
are more extreme than an in vivo environment where the body is able to transfer excess heat
away from local tissues through fluid flow.

2.2.1.2.

Force Measurements

Given the correlation between ultrasound and bone healing and how previous work has
shown that high intensity ultrasound produces a measurable acoustic radiation force,289 the
purpose of the following experiments was to investigate if low intensity ultrasound (<1 W/cm 2
spatial intensity) produces a detectable physical force as well. Also, testing would verify the
system could produce a controlled and measurable force which may be beneficial to
understanding bone repair in regards to the cellular and environmental response to the force.
In order to measure the force produced by the ultrasound system, a setup was engineered from
raw materials using a small ~12” tall table with four legs which held a Mettler Toledo digital
scale. On the bottom of the scale, from the weigh hook hung a clip which held two wires that
suspended a cone target. The cone was situated in an insulated water bath bu cket, and the
transducer was immersed and positioned directly and uniaxially approximately 1/8” above the
cone secured by a clamp and ring stand. The transducer produced an ultrasonic beam which
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propagated through the water resulting in a momentum transfer to the cone. A drawing and

Figure 15. Mass balance setup showing a schematic drawing (top) and the transducer
suspended over the hanging cone in water within an insulating rubber bucket (bottom).
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image of the setup can be seen in figure 15. With the following equations, the intensity of the
ultrasound beam was calculated from the measured load at each amplitude and duty cycle:

𝑝 = 𝑊𝑔𝑐

where:
𝑒𝑟𝑔𝑠
]
𝑠𝑒𝑐
𝑊 = 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑚𝑎𝑠𝑠 [𝑔𝑟𝑎𝑚𝑠]
𝑝 = 𝑝𝑜𝑤𝑒𝑟 [

𝑔 = 𝑎𝑐𝑐𝑒𝑙𝑒𝑟𝑎𝑡𝑖𝑜𝑛 𝑑𝑢𝑒 𝑡𝑜 𝑔𝑟𝑎𝑣𝑖𝑡𝑦 [𝑑𝑦𝑛𝑒𝑠]
𝑐𝑚
𝑐 = 𝑠𝑝𝑒𝑒𝑑 𝑜𝑓 𝑝𝑟𝑜𝑝𝑎𝑔𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑜𝑢𝑛𝑑 [ ]
𝑠𝑒𝑐

Further simplifying and assuming constant values for 𝑔 and 𝑐, the following equation is
yielded:
𝑃 = 14.65𝑤

where:
𝑃 = 𝑝𝑜𝑤𝑒𝑟 𝑜𝑓 𝑢𝑙𝑡𝑟𝑎𝑠𝑜𝑢𝑛𝑑 𝑏𝑒𝑎𝑚 [𝑊𝑎𝑡𝑡𝑠]
𝑤 = 𝑓𝑜𝑟𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑢𝑙𝑡𝑟𝑎𝑠𝑜𝑢𝑛𝑑 𝑏𝑒𝑎𝑚 [𝑔𝑟𝑎𝑚𝑠]

Beam power can be converted into spatial intensity (I) by dividing by the cross-sectional area
of the beam. Given that spatial intensity is normalized to the size of the transducer, it is a
universally recognized and standard measurement allowing for clinical comparisons of
ultrasound systems. As discussed earlier, the FDA approved the use of LIPUS treatment for
fracture healing applications with a spatial intensity of 30 mW/cm 2. With the transducer used
in this study having a nominal element size (diameter) of 0.75” or 1.905 cm, spatial intensity
was calculated by dividing the power of the ultrasound beam by the cross-sectional area of the
beam:
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𝐼=

𝑃 ∗ 1000
0.25𝜋1.9052

where:
𝐼 = 𝑠𝑝𝑎𝑡𝑖𝑎𝑙 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 [

𝑚𝑊
]
𝑐𝑚2

𝑃 = 𝑝𝑜𝑤𝑒𝑟 𝑜𝑓 𝑡ℎ𝑒 𝑢𝑙𝑡𝑟𝑎𝑠𝑜𝑢𝑛𝑑 𝑏𝑒𝑎𝑚 [𝑊𝑎𝑡𝑡𝑠]

Notably, the FDA approved spatial intensity of 30 mW/cm 2 would result in a load of 6
mg, or 0.059 N. Using clinically prescribed parameters, loads were measured for a series of
amplitudes (peak-to-peak voltage values) of a 1 MHz carrier signal with a pulse repetition
frequency of 1 kHz at a 20% duty cycle. Importantly, a 1 kHz pulse repetition frequency

Figure 16. A plot of applied force as a function of amplitude of a 1 MHz carrier signal, 1 kHz
pulse repetition frequency, and 20% duty cycle.

equates to a 1 ms, or 1000 µs, burst period. Hence a signal with these parameters at a 20%
duty cycle results in a signal burst of 200 µs and a pause of 800 µs. Measured loads can be
seen in figure 16. A measurable physical load was present when LIPUS was applied using the
clinical parameters. Additionally, it is observed that as amplitude increases, the measured load
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increased as well. In order to produce the clinically relevant intensity of 30 mW/cm 2, an
amplitude of ~160 mVpp is necessary at the 20% duty cycle. A linear relations hip was
determined between the applied voltage and the resulting load for the waveform tested.
Importantly, the significance of the data is that there is a predictable force output given certain
input parameters and that a wide range of physical loads can be produced with accuracy by
varying amplitude. Given that the system is highly tunable, its potential use for experiments
or therapies may be vast and go far beyond orthopedic applications.

2.2.1.3.

Cell Viability from LIPUS Treatment

Figure 17. Total protein assay to investigate cell viability of MC3T3 cells treated with and
without LIPUS over 3, 7, and 14 days.

In order to test the viability of the designed ultrasound system for in vitro cell studies,
MC3T3 osteoblast-like cells were cultured on tissue culture polystyrene (TCP) for 3, 7, and 14
days. An amount of 50,000 cells were cultured per well in 6 well plates (n=3) with α -MEM
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media supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin
(P/S). The experimental group was treated with the clinically prescribed parameters of LIPUS
for 20 minutes per day. The group receiving no treatment was the control group. Proliferation
of MC3T3 osteoblasts was determined by using a total protein assay (Thermo Scientific), and
compared to cells not exposed to LIPUS over the same time period, to assess any effects of
LIPUS on proliferation as plotted below in Figure 17. Importantly, groups treated with LIPUS
did not experience any negative effects in terms of proliferation over the 14 day time period.

2.2.2. LIPUS Deformation of Cells and Gels

Ultrasonic radiation force was produced using a 1.2 MHz unfocused immersion
transducer with a 1” nominal element size (Olympus NDT, Inc. Waltham MA) while
submerged in cell culture media (DMEM). An ultrasound signal was generated with a carrier
frequency of 1 MHz and amplitude that ranged from 20mV–500mV, which was pulsed at 1
kHz. The purpose of this study was to determine what mechanical effects, if any, that LIPUS
imparts on cells and 3-dimensional (3-D) scaffolds in the form of hydrogels via the use of
fluorescent imaging. Imaging of GFP cells under LIPUS was performed using a Nikon optical
microscope equipped with epifluorescence, and a water-cooled digital camera (Hamamatsu,
Inc.). Images were collected and evaluated using Volocity Software (Improvision, Inc.).
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2.2.2.1.

Macrophage Displacement from Ultrasound

LIPUS (50% duty cycle, 500mV amplitude) was applied to macrophages with GFP
actin seeded on tissue culture polystyrene and submerged in cell culture media.

Macrophage

imaging before, during, and after LIPUS exposure (1 minute off, 2 minutes on, 2 minutes off;
10 μm z-stack images acquired every 30 seconds) revealed both cell deformation/displacement
by approximately 1μm with subsequent partial recovery, and enhanced actin activity at the
10μ

Pre-LIPUS

In situ LIPUS (ultrasound pulsing)

Recovery (post LIPUS)

Figure 18. X-Z plane images of GFP actin labeled macrophages before, during, and after
exposure to a 1 MHz, 50% duty cycle, 500mV amplitude ultrasound treatment indicate

evident Z-plane deformation and displacement with subsequent recovery after exposure
ended.

basal plane during and after LIPUS administration as seen in figure 18. Given that cellular
deformation/displacement was evident from cells seeded on TCP, further investigation was
necessary to report what mechanical effects LIPUS could have on 3-D hydrogel structures.

2.2.2.2.

Beads in Puramatrix

Puramatrix, a commercially available, self-assembling peptide hydrogel (BD), was
used as a synthetic extra cellular matrix (ECM) and was reconstituted according to
manufacturer’s instructions. Briefly, the hydrogel stock solution (1% w/v) was sonicated f or
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10μ
m

Pre-LIPUS

In situ LIPUS (ultrasound pulsing)

Recovery (post LIPUS)

Figure 19. Z-plane images of fluorescent particles within the Puramatrix hydrogel before,
during, and after ultrasound treatment. Based on the initial position of the beads in the
first frame on the left, dotted yellow lines were added to help identify particle movement
throughout exposure and recovery periods.

30 minutes and pipetted into a culture well plate. The solution was then diluted into three
separate concentrations (1%, 0.5%, 0.25%), pipetted onto a glass cover slip, mixed with salt
solution and allowed to gel for 30 minutes at room temperature. The salt solution was
replenished twice over 60 minutes. To visualize the movement of the matrix under LIPUS
stimulation, 10 µl of a fluorescent 1-µm diameter polystyrene (Fluoro-Max) bead suspension
(Thermo Scientific) was pipetted into each well prior to gelation. Hydrogels were exposed to
ultrasound with a carrier frequency of 1 MHz and an amplitude of 500mV, pulsed at 1 kHz.
Duty cycle of the pulse ranged from 20%-100%. Using the same imaging parameters as
indicated with the macrophage displacement, microscopy images acquired over time indicated
a movement of beads of approximately 4 μm when subjected to a 1 MHz continuous (100%
duty cycle) ultrasound signal as shown in figure 19. Bead displacement proved that acoustic
radiation force does in fact result in deformable matrices which can be controlled by LIPUS
intensity.
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2.3. Detailed Summary of Research Objectives

2.3.1. Specific Aim I

For characterization of ultrasound and collagen hydrogels, tunable ultrasound system
will be designed so that various parameters and output (most notably spatial intensity) can be
controlled. A hydrophone will be used to calibrate the system’s output duri ng an amplitude
sweep and at different duty cycles. Next, type I collagen hydrogels will be constructed at a
range of optimal working viscosities. A rheometer will test the viscosity of the hydrogels
based on their collagen concentration. Fluorescent beads will be encapsulated into four
different collagen concentrations. The hydrogels will be fluorescently imaged before, during,
and after ultrasound treatment at the clinical parameters as well as other duty cycles and
intensity.

Volocity image analysis software will acquire z-stack images of the samples

throughout the runs and subsequently quantify bead deformation in total displacement as well
as x, y, and z directions.

2.3.2. Specific Aim II

To evaluate the effect of LIPUS in vitro, MC3T3 cells will be cultured on TCP and
encapsulated in three different concentrations of collagen hydrogels. Ultrasound treatment
will be provided using the clinical LIPUS parameters for 20 minutes per day by submerging
the transducers in culture media 3 mm above the cells on TCP or hydrogels. RT-PCR analysis
will be performed with osteogenic markers for the TCP study with 3, 7, 14 and 21 day time
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points. The same analysis will be performed for each concentration of hydrogels although the
time points will be 1, 3, and 7 days. Additionally, shorter term studies will be performed where
COX-2 expression, an indicator of mechanical transduction, will be detected in hydrogels
immediately after LIPUS treatment and 30 minutes after treatment. Based on results, varying
intensities may be used to analyze if COX-2 expression is affected.

2.3.3. Specific Aim III

In vivo analysis in the last study will show the efficacy of the combined treatment of
LIPUS with an injectable BMSC-encapsulated collagen hydrogel over a healing time of 2 or 4
weeks in a mouse calvarial defect model. LIPUS will be administered for five of every seven
days of the week with ultrasound gel coupled between the transducer and skin over the defect
site. As this study is the first ultrasound in vivo experiment in our lab, it will be performed as
a pilot study with a limited number of groups, but will lay the groundwork for future
investigations. The groups will consist of the hydrogels with encapsulated cells without LIPUS
treatment (control) and hydrogels with cells and with LIPUS treatment (experimental).
Samples will be evaluated with x-ray imaging, and histological analysis will be performed on
samples to evaluate the extent of donor cell survival, new bone formation, mineralization, and
remodeling.
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3. SPECIFIC AIM I: CHARACTERIZATION OF ULTRASOUND AND COLLAGEN
HYDROGELS

3.1. Introduction

As indicated earlier, ultrasound is used clinically in many various modalities including
diagnostics, therapeutics, surgical, and imaging. As an orthopedic laboratory, of particular
interest to our research is the lower intensity ultrasound which has served as a beneficial
therapy for fractures and non-union defects over the past two decades.

However, the

commercially available units such as the one manufactured by Smith and Nephew all use the
same or similar therapeutic ultrasound parameters in terms of carrier frequency, pulse
repetition frequency, duty cycle and spatial intensity as well as the duration of treatment.
Additionally, the limited knowledge of how LIPUS works is left to studies investigating
cellular signaling and the resulting macro scale bone formation.290

In order for a

comprehensive investigation of the beneficial effects of LIPUS, the steps between LIPUS
therapy and ultimate bone formation/healing must be better understood to maximize the utility
of this technology. The preliminary data has shown that LIPUS generates a measurable
acoustic radiation force, and it is our hypothesis that this force may be the underlying
mechanism initiating the cascade of events leading to healing. And in order to ultimately better
understand ultrasound and its bioeffects, we needed to create a highly tunable system where
we could control each of the parameters listed above, not only for the work in this thesis, but
for many future studies to come as well.
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And in combination of the currently clinically used LIPUS therapy, we needed a way
to analyze the response of the physical force of LIPUS both in tissue mimetics where we proved
the feasibility with the PuraMatrix and also with a relevant biomaterial scaffold which could
be incorporated for bone tissue engineering. After some consideration, type I collagen seemed
a logical choice in terms of workability and its capability for bone cell encapsulation. As bone
is a composite tissue, it contains both organic and inorganic material. Type I collagen would
be a good starting point to simultaneously characterize the ultrasound system via parameters
affecting acoustic radiation force and additionally encapsulate bone cells, particularly
osteoblasts which are native to collagen in bone formation and extracellular matrix. With a
properly designed and characterized ultrasound system and naturally occurring threedimensional scaffold such as a type I collagen hydrogel, we had the capability and laid the
ground work to run many experiments. The characterized ultrasound system and collagen
hydrogels could be used to address the relationship between LIPUS generated acoustic
radiation force on: tissue deformation; cellular movement and/or deformation; cellular genetic
response; and an in vivo defect in hopes to tie some of the results and concepts together.
Importantly, by adjusting ultrasound parameters of interest along with collagen hydrogel
composition, we could investigate how cells respond to different treatments and attempt to
understand the underlying mechanisms of ultrasound efficacy.
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3.2. Materials and Methods

3.2.1. Ultrasound System Characterization and Quantification of Force,
Pressure, and Intensity

As discussed in the preliminary data, the tunable ultrasound system consisted of using
a 1.2 MHz unfocused immersion transducer (Olympus), a waveform generator (Agilent), and
an ENI RF amplifier (Bell Electronics) and calibrated with a mass balance & reflecting target
cone setup and a 200 μm diameter needle hydrophone (Onda). A 1 MHz carrier frequency, 1
kHz pulse repetition frequency, and 20, 50 and 100% duty cycle was tested for output using
an amplitude sweep in order to find the proper amplitude to produce a 30 mW/cm 2 spatial
intensity (clinically approved intensity for fracture healing). The acquired data was used to
calculate values for force, intensity and pressure which will be plotted against amplitude (input
voltage). Importantly, best fit curves were calculated to provide the necessary calibration plots
from the acquired data so that in vitro and in vivo studies can be performed with the desired
output parameters based on the input settings on the waveform generator.
As shown in the preliminary data, the mass balance and cone setup was able to detect
forces from the ultrasound system which can be translated into intensity.

However, a

hydrophone can provide a much higher resolution to detect instantaneous acoustic pressures in
water.291 The hydrophone has a membrane and based on its amount of deflection, can output
a voltage detected by an oscilloscope. During the amplitude sweeps, voltages were recorded
and used in an equation including the hydrophone calibration factor provided in documentation
supplied by the vendor.

The resulting hydrophone calculations were used to provide

instantaneous pressure (kPa) which subsequent calculations were used to convert the pressure
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to a spatial intensity to relate the values to clinical relevance. The hydrophone and ultrasound

Figure 20. Schematic drawing of the hydrophone testing setup (top) and a picture of the
setup (bottom) with the clamps holding the transducer and hydrophone uniaxially and
allowing for distance between the two pieces of equipment to be changed.
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transducer were oriented uniaxially with a clamp holder approximately 1/8” apart submerged
under DI water in a fish tank to maintain consistency with cell culture and in vivo setups (figure
19). As can be seen in the equations below, the hydrophone’s output voltage was converted
into a pressure based on a sensitivity factor provided by the manufacturer. Additionally, the
sensitivity factor is also dependent on the experimental frequency.

𝑝=

𝑉
𝑀(𝑓)

(Equation 1)

𝑝: acoustic pressure [kPa]
𝑉: measured voltage [mV]
𝑀(𝑓)*: sensitivity of hydrophone as a function of frequency [mV/MPa]
*Note: sensitivity factor must be corrected, see below.

However, as noted above, the sensitivity factor 𝑀(𝑓) is dependent on the experimental
frequency and was calibrated by the manufacturer. Additionally, depending on one’s setup, a
corrected sensitivity factor must be calculated as indicated in the equation below taking into
account the gain of the preamplifier (AH-2010, Onda), the experimental frequency, and the
capacitance of the hydrophone (HNC-0200, Onda) and preamplifier [ALUM/NEMA, 1998;
IEC 62127-2, 2007]. Once the corrected sensitivity factor was calculated, it was used in
Equation 1 above to solve for pressure.
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𝑀𝐿 (𝑓) = 𝐺(𝑓)𝑀𝐶 (𝑓)

𝐶𝐻
𝐶𝐻 + 𝐶𝐴

(Equation 2)

𝐺(𝑓): gain of preamplifier
𝑀𝐶 (𝑓): sensitivity of hydrophone as a function of frequency [mV/MPa]
𝐶𝐻 : capacitance of hydrophone (pF)
𝐶𝐴 : capacitance of preamplifier (pF)
𝑀𝐿 (𝑓): corrected sensitivity factor of the hydrophone/preamplifier setup

To convert the calculated pressure values to the clinically relevant parameter,
instantaneous acoustic intensity was converted by the equation below.

𝐼=

𝑝2
𝜌𝑐

(Equation 3)

𝐼: Instantaneous acoustic intensity [mW/cm 2]
𝑝: acoustic pressure [kPa]
𝜌: density of the propagating medium [H 2O @ RT: 1000 kg/m 3]
𝑐: velocity of sound in the propagating medium [H 2O @ RT: 1480 m/s]

The calculated data for pressure and intensity was plotted against amplitude and best
fit curves were calculated and added to provide the calibration plots. We hypothesized that as
amplitude and duty cycle increased, intensity would increase as well.
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3.2.2. Collagen Hydrogel Characterization via Rheology and SEM

In order to conduct cell studies and understand the relationship between gel stiffness
and concentration, mechanical properties of various Type I rat tail collagen (BD Biosciences)
hydrogels ranging from 1mg/mL ‐ 5mg/mL, which resembled optimal viscosities for injectable

Figure 21. Picture of the experimental rheometry setup after the collagen hydrogel was
analyzed.

bone tissue mechanics, were tested using a rheometer (TA Instruments). Important to note in
terms of collagen hydrogel concentration is that the percentage composition of collagen is
related to the mass (milligrams) per volume (milliliter) by a factor of 10. For example, 0.1%
collagen is equivalent to 1 mg/mL collagen, and 0.2% collagen is equivalent to 2 mg/mL. The
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Figure 23. Hydrogel molds made out of acrylic allowed for the uniform fabrication and
transport of collagen hydrogels.

Figure 22. Hydrogels flash frozen in the liquid nitrogen setup (right) and then freeze-

fractured and dehydrated in liquid nitrogen (left) before lyophilization.

collagen hydrogels were made according to the manufacturer’s protocol. The rat tail collagen
stock solution was maintained in acetic acid at 4°C. The stock solution, NaOH, and two
additional reagents were mixed on ice, and then were placed on the rheometer’s stage between
a preheated parallel‐plate at 37°C where the solution quickly gelated (figure 21). The parallel-
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Figure 24. Freeze-fractured hydrogel cross-sectional pieces sputter-coated with goldpalladium.

plate used had a 12mm diameter geometry and obtained the storage and loss modulus of
collagen hydrogels. A maximum strain was set at 0.1% within the 10% linear viscoelastic
regime for shear measurements.292 An n =3 was used and the data was plotted.
Additionally, collagen hydrogels of the same concentrations as listed above were
fabricated in molds in a 37°C incubator for 30 minutes (figure 22). They were then removed
and individually flash frozen in liquid nitrogen and freeze fractured to image the cross sections
(figure 23). The samples were lyophilized for 24+ hours and subsequently sputter coated with
gold-palladium for 1 minute at 50mA (15nm thickness) (figure 24). Each concentration
hydrogel was imaged on an SEM at magnifications of 100, 400, 1,000 and 2,000X in order to
see the internal structure of the scaffolds.
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3.2.3. Mechanical loading of hydrogels via ultrasound and quantification of
deformation via fluorescent imaging

Figure 25. 3-D printed culture inserts used to visualize the hydrogels undergoing LIPUS
stimulation.

Rat tail Collagen Type I hydrogels (0.5, 0.75, 1, and 2 mg/mL) were formed with
encapsulated fluorescent 1µm beads and imaged with a water-cooled epifluorescent
microscope using Volocity (Improvision) acquisition and quantification software. Hydrogels
were manufactured in 3-D printed acrylic wells custom fit for the fluorescent microscope used
(figure 25). Additionally, removeable holding plates were 3-D printed which each held two
wells and could be stored in the larger 3-D printed base which could fit a total of six wells for
ease of transport between hydrogel manufacturing within the incubator and the final
microscopy setup destination (figure 26). For timing, the first 30 seconds had no treatment to
establish a baseline, with the following 30 seconds subjected to ultrasound treatment, and the
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Figure 26. 3-D printed culture insert with hydrogel undergoing LIPUS stimulation during
fluorescent imaging.

final 30 seconds no treatment was provided in order to visualize any scaffold deformation and
relaxation.

By acquiring z-stack images over time, fluorescent beads were tracked and

movements were averaged to determine the average deformation of the various viscosity
hydrogels under variable loads and quantified in the total directional movement, and the x, y,
and z directional movements as well. Additionally, the various viscosity hydrogels were
subjected to the clinical parameters for fracture healing as noted earlier (30 mW/cm2 at 20%
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duty cycle and 1 kHz pulse repetition frequency) and the amplitude was held constant for the
50 and 100% duty cycle runs. The ultrasound transducer was submerged in 2 mL of media
centered within the well directly over the hydrogel being tested. The ultrasound transducer
was positioned and lowered using adjustable clamps and ring-stand, and the fluorescent
microscope was stabilized as it was situated on an air table to limit any environmental
vibrations and noise. Also, a higher intensity LIPUS treatment was used with a stiffer gel (2
mg/mL) to verify that some deformation can still occur if the intensity/load is increased.
Intuitively, we hypothesized that the lowest viscosity hydrogels would experience the greatest
deformation in addition to higher duty cycles causing greater deformation.
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3.3. Results

3.3.1. Ultrasound System Characterization and Quantification of Force,
Pressure, and Intensity

The mathematically derived relationship between spatial intensity and pressure can be
seen in figure 27.293 Although self-evident based on Equation 3, it was important to establish
and plot the positive proportionality between spatial intensity and pressure when using the
high-resolution hydrophone. As hypothesized, with an increase in amplitude on the waveform
generator, the resultant force increased as well as can be seen in figure 28. Intuitively,
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amplitude was proportional to force generated. Additionally, as duty cycle increased, so did
the force at the same particular amplitude. With a higher duty cycle, the waveform is generated
for a longer time period (or greater percentage of time), resulting in generating a greater
mechanical response through the transducer, hence manifested a greater force. Force was
directly related to the designated amplitude and duty cycle.

Next, with a simple mathematical equation noted earlier (Equation 3), spatial intensity
is proportional to force; hence as amplitude or duty cycle increased and created a greater force
or pressure (force per unit area), the calculated spatial intensity increased as seen in figure 29.
To reiterate, spatial intensity is the power per unit area (for our purposes measured in mW/cm 2)
and is perhaps the most important clinical parameter.
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Figure 27. Amplitude sweep with varying duty cycles with calculated special intensity
output.

To show the relative forces that a given duty cycle produces compared to a continuous
signal (or 100% duty cycle), the correlation between the amplitude sweeps of the 20% and
50% duty cycles, or 200µs and 500µs pulses respectively, when using a 1,000µs pulse
repetition frequency, was plotted by the percentage mass at each amplitude in comparison to
the continuous waveform (figure 30).

With the exception of very low amplitudes, the

theoretical values matched up very closely to the experimental values. The 20% and 50% duty
cycles each produced about 20% and 50% of the mass (or force) that the 100% duty cycle, or
continuous, waveform generated.

100

Figure 28. Amplitude sweep with varying duty cycles compared as percentages of the
continuous waveform in mass.

Figure 31 shows the amplitude sweeps and correlated spatial intensities using the
hydrophone setup with two different amplifiers that were purchased so that more than one
ultrasound setup could be used for in vitro or in vivo experiments at once. We had to be
conscious of the particular amplifier and amplitude chosen so that the desired output was
always as expected from extrapolated values from the data set. As the two amplifiers had
slightly different gains, one amplifier would output a different voltage than the other for a
given amplitude. In order to keep consistency for output for both setups, we had to be
conscious at all times of which amplifier was being used so that proper input values would
correlate with consistent and exact outputs for both ultrasound setups. Also plotted is the
spatial intensity for the cone and balance setup previously used in the preliminary data section.
The spatial intensity values for the cone and balance setup provided a second verification to
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validate that hydrophone was outputting appropriate data. Additionally, both calculated best
fit lines closely correlated with the amplitude sweeps for each ultrasound setup with both
values of R2 > 0.99.

Figure 29. Amplitude sweep with varying duty cycles with calculated special intensity
output.
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3.3.2. Collagen Hydrogel Characterization via Rheology and SEM

As hypothesized, the relationship between the collagen concentration within the
fabricated hydrogels and the storage and loss moduli was directly proportional (figure 32).
More collagen within a hydrogel provided a more rigid, yet resilient scaffold which in turn
could be useful when designing scaffolds for particular tissue engineering applications.
However, at the highest collagen concentration, 5 mg/mL, the viscosity of the hydrogel was
rather high and may make it difficult for cellular proliferation, migration, communication, and
waste transport, which may need to be investigated further. The data provided evidence of the
viscoelastic nature of the collagen hydrogels given that their response is not purely elastic as
expressed from the loss moduli plotted.
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Figure 30. Storage moduli (top) and loss moduli (bottom) of collagen hydrogels.
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Figure 31. SEM images of 0.1% collagen hydrogels at 100, 400, 1,000, and 2,000X.
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Figure 32. SEM images of 0.3% collagen hydrogels at 100, 400, 1,000, and 2,000X.
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Figure 33. SEM images of 0.5% collagen hydrogels at 100, 400, 1,000, and 2,000X.

107

Figure 34. SEM images of 0.5% collagen hydrogels at 400, 1,000, 2,000, and 5,000X.

SEM imaging of three different concentrations of collagen hydrogels after freeze
fracturing, lyophilizing, and sputter coating showed different morphology and porosity as
concentration changed from 0.1% collagen in figure 33, 0.3% collagen in figure 34, and 0.5%
collagen in figure 35. Figure 36 has additional images of the 0.5% collagen hydrogel at higher
magnifications: 400, 1,000, 2,000, and 5,000X. The lowest hydrogel concentrations appeared
to have the largest pores and were the least dense in terms of matrix. As higher collagen
concentrations have a higher ratio of solid mass compared to water, intuitively the scaffolds
were noticeably denser in matrix composition. It appears that a ~10µm cell would be able to
infiltrate the collagen fiber network of a 0.1% collagen hydrogel but may be difficult to migrate
through a 0.5% collagen hydrogel. However, based on the flexibility and elasticity of the
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higher concentration collagen hydrogels investigated, encapsulated cells may be able to attach
and displace collagen fibers and receive nutrients or growth factors via fluid exchange through
the scaffold.
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3.3.3. Mechanical loading of hydrogels via ultrasound and quantification of
deformation via fluorescent imaging

Figure 35. Mean displacement of fluorescent beads every 1.5 seconds in four different
collagen hydrogel concentrations from LIPUS treatments of 20, 50 and 100% duty cycles.

The fluorescent beads encapsulated within the collagen hydrogels showed displacement
from both the onset and cessation of ultrasound, suggesting that the hydrogel deformation
occurred when exposed to ultrasound treatment, and subsequent recovery occurred at treatment
cessation. While fluorescent microscopy imaging was performed using Volocity analysis
software, the mean bead displacements (absolute value) in each of four different hydrogel
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concentrations (0.5, 0.75, 1, and 2 mg/mL) were plotted every 1.5 seconds as shown in figure
37. LIPUS was turned on at 30 seconds and turned off at 60 seconds, and beads were tracked
for a total of 90 seconds. Given that the encapsulated beads were randomly distributed
throughout the hydrogel, the mean displacement of beads was assumed to be indicative of the
general deformation the hydrogel experienced. This assumption was made in part due to the
fact that the fluorescent beacons were composed of polystyrene, a synthetic aromatic polymer
similar in density (1.04 g/cm3) to that of water, hence physical movements should not have
differed significantly from the surrounding hydrogel substrate given its similar nature. 294
The greatest deformation of the hydrogels occurred with the lowest collagen
concentration and hence the lowest storage modulus. Hydrogel deformation was therefore
indirectly proportional to collagen concentration. Hence as collagen concentration increased
and storage modulus increased, mean bead displacement decreased. The majority of the gel
deformation occurred as LIPUS was turned on, or acoustic radiation force was applied. Bead
displacement spiked during the two or three 1.5 second intervals when the acoustic radiation
force was applied. After the initial deformation, there was little bead displacement until 60
seconds when LIPUS was turned off and the acoustic radiation force was no longer applied.
The second increase in displacement occurred around the 60 second time intervals, but was
slightly lower than the initial bead displacement within that hydrogel when LIPUS was applied
at 30 seconds. Since the mean bead displacements plotted in figure 37 are absolute values, it
is apparent that the hydrogels were likely deformed in one direction to a particular point of
equilibrium between the acoustic radiation force and the elasticity of the collagen h ydrogel
applying an equal and opposite force and then recovered in the other direction. Once LIPUS
was turned off, the hydrogels relaxed and returned back near their original positions. Given
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the viscoelastic properties of the hydrogels indicated by the rheology testing, it is intuitive that
the hydrogels experienced a higher degree of bead displacement at the initial application of
LIPUS compared to their recovery displacement when LIPUS was stopped. The hydrogels did
not fully recover to their exact initial positions due to the loss in energy from the viscous
portion of the hydrogel.
In addition to collagen concentration being a factor in mean bead displacement, as we
would expect the greater the duty cycle, the greater the beads were displaced as a greater force
was applied. The bead displacement that occurred right at 30 seconds when LIPUS was turned
on for about two or three 1.5 second intervals was greatest with the 100% duty cycle, slightly
less with the 50% duty cycle, and the least with the 20% duty cycle. As mentioned before, the
lowest concentration hydrogel experienced the greatest deformation and each gel experienced
slightly less deformation as their collagen concentration increased. However, at the 2 mg/mL
hydrogel, little to no deformation was accounted for, indicating that the particular collagen
concentration was the upper limit for the particular loads being applied considering amplitude
was held constant for all three duty cycles and the 20% duty cycle expressed the clinical
intensity of 30 mW/cm 2. To verify that the 2 mg/mL collagen hydrogel was simply at the
study’s limit in terms of applied force and no deformation being present, we increased the
amplitude of our signal which immediately resulted in noticeable bead displacement again.
Rather than looking at bead movement at short intervals, the total mean path length was
calculated for each of the gels and duty cycles as seen in figure 38. Once again, as collagen
concentration increased, gel deformation was assumed to have decreased as mean path length
decreased in all but one group, the 0.1% collagen gel, which appeared to be an outlier.
Additionally, as duty cycle increased, so did the mean path length as would be assumed since
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a greater force was being applied. As shown in figure 39, mean path lengths were split up into
separate time intervals, displaying that the beads traveled the most during LIPUS treatment
and usually more with higher duty cycles. Mean path length was the least before ultrasound
was applied fairly consistently throughout the groups and simply represents noise and
Brownian motion. The mean path length was the second greatest during the post ultrasound
phase when the hydrogels were recovering. Additionally, mean path lengths were separated
into total mean path length (meaning in any direction), and then represented in the x, y, and z
coordinates individually. The acoustic radiation force was applied to the hydrogels directly
on top by submerging the transducer in the media. The transducer was uniaxially aligned with
the z axis; however, the majority of the bead deformation did not occur in the z -direction.
Most of the bead displacement was actually in the x,y plane.

Mean Path Length (µm) Traveled over the Entire 90 Seconds in all Directions
0.05% Collagen
Duty Cycle Mean Path Length (µm)
20%
50%
100%

36.63
35.95
58.88

0.075% Collagen
STDEV
18.36
9.14
19.67

Mean Path Length (µm)
13.01
15.68
29.86

0.1% Collagen

STDEV
6.34
2.10
1.72

Mean Path Length (µm)
19.59
26.49
31.57

0.2% Collagen
STDEV
3.15
3.84
9.49

Mean Path Length (µm)
6.39
6.15
8.62

Figure 36. Mean path length of beads traveled during the entire 90 seconds.
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STDEV
5.07
2.25
3.54

Mean Path Length (µm)Traveled within the Separate Time Frames (XYZ):
20%
Pre

During

50%
Post

Pre

During

100%
Post

Pre

During

Post

% Col AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV
0.05% 2.72 1.99 28.51 8.62 6.87 11.58 2.24 1.29 32.11 7.92 1.60 0.41 3.16 1.46 55.38 19.46 2.11 0.50
0.075% 2.49 1.43 7.35 1.48 2.90 3.73 2.16 0.99 11.48 0.85 1.93 0.83 1.81 0.41 26.00 0.60 1.91 0.80
0.1% 5.56 0.59 7.36 0.34 4.10 0.50 9.56 1.07 14.35 0.66 4.46 0.60 12.96 1.75 15.02 1.91 4.48 0.81
0.2% 2.41 2.56 2.33 1.37 1.64 1.20 1.89 0.76 2.46 0.90 1.80 0.68 3.02 1.11 3.45 1.53 2.15 0.98

Mean Path Length (µm)Traveled within the Separate Time Frames (X):
Pre

20%
During

Post

Pre

50%
During

Post

Pre

100%
During

Post
% Col AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV
0.05% 0.53 0.33 10.96 1.89 0.94 0.31 0.41 0.15 14.91 1.58 1.18 0.20 1.13 0.24 21.19 3.91 1.73 0.47
0.075% 1.46 0.20 3.79 0.18 1.52 0.52 1.28 0.24 7.41 1.03 1.52 0.27 2.01 0.06 14.11 0.13 2.69 0.08
0.1% 4.16 0.45 5.85 0.17 3.03 0.15 6.82 0.24 12.54 0.38 3.45 0.13 10.14 2.07 12.56 1.15 3.06 0.21
0.2% 0.39 0.11 0.43 0.19 0.29 0.13 0.85 1.29 0.69 0.74 0.59 0.84 0.67 0.15 0.95 0.35 0.35 0.17

Mean Path Length (µm)Traveled within the Separate Time Frames (Y):
Pre

20%
During

Post

Pre

50%
During

Post

Pre

100%
During

Post
% Col AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV
0.05% 0.67 0.27 5.51 2.29 0.83 0.32 0.47 0.12 19.10 4.45 2.97 0.80 0.86 0.32 33.00 11.86 4.78 1.36
0.075% 0.70 0.18 2.58 0.36 1.18 1.64 0.59 0.16 5.35 0.84 1.19 0.54 0.75 0.09 10.71 0.10 1.25 0.17
0.1% 6.59 0.82 8.72 1.43 4.28 1.33 8.55 2.22 12.38 2.20 5.56 1.37 7.57 1.72 18.46 6.61 5.40 1.79
0.2% 0.38 0.18 0.42 0.11 0.31 0.15 0.67 0.85 0.95 0.63 0.54 0.70 1.54 0.39 0.73 0.34 0.44 0.20

Mean Path Length (µm)Traveled within the Separate Time Frames (Z):
Pre

20%
During

Post

Pre

50%
During

Post

Pre

100%
During

Post

% Col AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV
0.05% 1.52 1.25 7.82 6.19 3.04 5.88 1.26 0.97 4.98 5.34 0.70 0.29 1.67 0.76 10.93 9.53 1.20 0.67
0.075% 0.86 0.70 1.12 0.73 0.78 0.74 0.73 0.50 1.08 0.72 0.73 0.40 0.49 0.19 0.93 0.30 0.71 0.32
0.1% 1.52 0.75 1.43 0.82 1.08 0.66 2.31 1.45 1.53 0.92 0.98 0.74 1.93 0.69 1.98 1.28 1.29 0.80
0.2% 1.56 2.22 1.06 0.73 0.78 0.69 1.71 2.20 1.50 1.23 1.20 1.08 1.34 0.75 1.34 0.68 0.99 0.46

Figure 37. Mean path length of beads traveled within separate time frames: before; during;
and after LIPUS.

114

3.4. Discussion

The highly tunable ultrasound system developed has allowed us to control the output
of force, pressure, spatial intensity, etc. by the use of the calibration curves which were
developed from amplitude sweeps and hydrophone output. By selecting a particular amplitude,
we can control any particular output desired for a study. Additionally, by selection of the
amplitude and/or duty cycle, we can control hydrogel deformation (in this case collagen
hydrogels) through the known amount of load being applied manifested at those particular
settings. A hydrogel of a particular concentration can be chosen as well for an application that
desires a particular stiffness, or storage modulus. The hydrophone allowed for real time
acquisition of pressures developed from the mechanical vibration expelled from the ultrasound
transducer. Where high intensity focused ultrasound (HIFU) can be used in acoustic radiation
force imaging295 in a technique known as elastography, 296 where the acoustic wave generated
can physically displace the tissue it propagates through, ultimately allowing for the
characterization of the tissue’s mechanical properties, 297 we wanted to investigate if LIPUS in
fact produced a measurable acoustic radiation force and if this force was great enough for
hydrogel deformation and in vitro and in vivo responses.
From our work, we also now know more about the behavior and integrity of the collagen
hydrogels. When acoustic radiation force was applied to the four collagen hydrogels of varying
stiffness, a fairly immediate and uniform deformation was experienced which was concluded
by the mean of ten bead displacements at every 1.5 second time interval. Through Wolff’s
law, we know that bone responds positively through physical force and is remodeled based on
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where forces are greater or lesser. The signal used in LIPUS therapy for fracture healing has
a pulse repetition frequency of 1 kHz with a carrier frequency of 1 or 1.5 MHz. That means
that the 1 or 1.5 MHz signal is pulsed or turned on 1,000 times per second and given that a
20% duty cycle is used that means that the signal is only on for 20% of that particular interval
during the pulse. Biologically speaking, a cell likely cannot distinguish a force applied 1,000
times per second any different than if the force was applied 500 times per second or 2,000
times per second. From the hydrogels response, it was evident that the load was felt as one
continuous load, hence why the hydrogels deformation took place in about three seconds and
then did not change until the load was removed (LIPUS was turned off) where the hydrogel
experienced almost full recovery evidenced from the mean bead displacement peaking slightly
less than its peak when the load was applied. The graphs show about an 80% recovery after
the acoustic radiation force is stopped.
We verified that hydrogels are in fact deforming in one direction under LIPUS and
returning back in the other direction during recovery by looking at the mean displacements in
all three individual coordinates in x, y, and z and not taking the absolute value. From this it is
evident that the hydrogels are deformed in one direction when loaded and recover back in the
other direction when unloaded. Additionally, the majority of the deformation did not occur in
the z-direction which is uniaxial to the acoustic radiation force. Typically the d eformation
would occur in the direction of the load; however, with our setup and limitations with the
microscope, it was only possible to image a z-stack (an x,y slice) up to about 100µm in the zdirection away from the surface of the coverslip. Based on the laws of laminar flow, molecules
of a fluid move the least close to the surface of the pipe or structure they reside in. Similarl y,
given that the z-stacks we acquired were only at maximum 100µm away from the coverslip,
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any movement of the beads bringing them closer to the surface of the coverslip would hinder
their further movement in theory. So despite the acoustic radiation force being applied in the
z-direction and based on how close the imaged beads were to the surface of the cover slip, the
beads ultimately moved in the x,y plane more than they did in the z-direction. The hydrogels
are over 99% water as well, and given that water is an incompressible fluid, the hydrogel could
not deform into a space that is smaller than it started with. When the acoustic radiation force
was applied in the z-direction, the beads had to move with fluids as they go from high pressure
to lower pressure areas. The greatest pressure would be closest to the coverslip so the beads
moved perpendicular to the acoustic radiation force in the x,y plane where pressure would
become less as they being to move out of the ultrasound beam. And based on laminar flow, if
the beads stayed higher in the z-direction, or avoided moving closer to the coverslip, then they
would experience less friction and be able to displace further in the x,y plane.
Also, mentioned before was the notion of the pulse repetition frequency of the typical
LIPUS signal in fracture healing. It was evidenced that the hydrogels only deformed that one
time at the instant the acoustic radiation force was applied. The only time the beads moved
again (besides Brownian motion) was when LIPUS was stopped. This is similar to stepping
on a scale to weigh yourself and stepping off. Since bone responds to physical loads positively
as expressed by Wolff’s law, perhaps there would be more benefit to not have a pulse repetition
frequency of 1 kHz where the carrier signal is applied 1,000 times per second. Subsequently,
the scaffolds and likely cells as well cannot distinguish the rate of that repetition frequency
and simply deform to a point of equilibrium for the duration of LIPUS treatment, which is 20
minutes per day clinically. Perhaps bone cells would respond better to a repeated loading and
unloading as described by Wolff’s law, meaning that a pulse repetition frequency around 1 Hz
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may be of greater benefit. With that parameter, the cells would be loaded and unloaded every
one second for the 20 minute treatment. The characterization of the ultrasound system allows
for the possibility to run many different studies and investigate many different parameters in
hopes to first optimize the LIPUS therapy and secondly discover the underlying mechanism of
action of its efficacy.
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4. SPECIFIC AIM II: EFFECT OF ULTRASOUND IN VITRO: CELLS AND
ENCAPSULATED CELL-HYDROGEL CONSTRUCTS

4.1. Introduction

With the development of a highly tunable ultrasound system, we have demonstrated via
the characterization with a needle hydrophone, the presence of a measurable acoustic radiation
force (ARF) even at low intensities such as what is used in low intensity pu lsed ultrasound
(LIPUS) where clinical effectiveness has been shown for years by the transdermal treatment
for fracture healing and non-union defect repair.272,279 Where ARF is traditionally recognized
in higher intensity medical ultrasound modalities such as diagnostics and imaging
techniques,230,289 we have now shown that LIPUS also produces a measurable ARF which may
be a driving factor in the long unidentified and underlying mechanism for the benefit s of
LIPUS in orthopedic healing, which we hypothesized holds a positive correlation. Other
groups have suggested that the efficacy of LIPUS may be derived from local heating effects,
which could lead to enhanced local blood flow. 298,299 However, with the designated limit in
local heating effects set by the FDA, long duration therapeutic ultrasound devices are not to
exceed 1°C in temperature increase. 300 One may question if LIPUS devices with a spatial
intensity limited by such a small temperature increase may be negligible to the benefits in local
tissue response. Additionally, blood flow and other fluid exchange may potentially and
quickly flush out any notable temperature changes in the area.
As mentioned earlier in Bioeffects of Ultrasound, there are three main mechanisms of
action with ultrasound: acoustic radiation force; acoustic torque; or acoustic streaming. As
there has been much in vitro work done investigating cellular responses to LIPUS, to our
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knowledge our work was the first to investigate the acoustic radiation force with deformable
scaffolds to not only osteogenic cellular markers, but particularly markers indicative of
mechanical stress. Beyond this work being done in vitro with pre-osteoblasts on tissue culture
polystyrene (TCP), importantly we extended our work to a more accurate cellular environment
to that which more closely exists in vivo via tissue mimetics and the collagen hydrogel threedimensional scaffolds. Where our in vitro work exposed our cells to acoustic radiation force
via the application of LIPUS from submerged ultrasound transducers in culture media,
encapsulated cell/hydrogel constructs were subjected to acoustic radiation force as well as
acoustic streaming, or fluid flow. Fluid flow is present in bone channels known as canaliculi
and manifests itself as a shear force as is well documented in literature specifically in the field
of mechanotransduction as previously discussed.237,301,302
To note, we demonstrated that LIPUS produces an acoustic radiation force during both
in vitro experiments as well as in vivo. Additionally, for the feasibility of the manifestation of
acoustic radiation force in translational research for the clinical realm, we verified that acoustic
radiation force does indeed pass through rat skin with about only a 10% attenuation (figure
40). Briefly, we validated this by using our acoustic radiation force cone and balance setup as
previously described; however, we coupled a layer of freshly harvested rat skin directly
adjacent to the ultrasound transducer to mimic the clinical transcutaneous treatment of LIPUS.
We performed an amplitude sweep with the ultrasound system and plotted the measured mass
from the balance for runs with and without the rat skin, holding all other parameters constant.
By calculation, the difference between the two measured forces for LIPUS treatment with and
without the layer of rat skin demonstrated only roughly 10% attenuation of the signal. It was
apparent that the phenomenon of acoustic radiation force is capable of propagating through

120

biological tissues; hence this allowed us to make assumptions beyond our in vitro experiments
that acoustic radiation force effects should be evaluated in vivo. Also, fluid flow is manifested
by LIPUS application in vitro as evidenced from data not shown; however, it was demonstrated
in preliminary studies where dye was dropped in a fish tank in front of the ultrasound
transducer resulting in the dye being propelled forward. However, evidence of proof of fluid
flow in vivo has yet to be confirmed, yet is a likely possibility taking all factors into account.

Comparison of 1 MHz Signal (with 1 kHz Pulse Repetition Frequency
and 20% Duty Cycle) Coupled with and without Rat Skin
8
7

Force (µN)

6
5

No rat skin

4

With rat skin

3
2
1
0

0

50

100

150

200

250

Waveform Generator Amplitude (mVpp)

Figure 38. Relationship between generated acoustic radiation force with a LIPUS setup
coupled with and without rat skin.
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4.2. Materials and Methods

Next, in order to evaluate the effect of LIPUS on cells alone (on TCP) and cells
encapsulated in collagen type I hydrogels, MC3T3-E1 cells, a well-documented preosteoblast
cell line derived from mouse calvaria, 303–306 were used for each of the studies, and qRT-PCR
was performed for common osteogenic markers. In both studies (on TCP and hydrogel
encapsulation), cells were cultured in alpha-MEM media supplemented with 10% FBS and 1%
Penicillin/Streptomycin purchased from Gibco (Grand Island, NY). For the TCP study, cells
were seeded at a density of 50,000 cells per well in a 6-well plate using the clinical intensity
of LIPUS (30 mW/cm2) (experimental group) over 3, 7, 14, and 21 day time points compared
to the group receiving no treatment (control group). RNA was extracted and isolated using the
Qiagen RNeasy kit (Valencia, CA) and converted to cDNA using Clontech’s EcoDry Premix
(Mountain View, CA) both based on the manufacturer’s protocols. qRT-PCR analysis was
performed using Taqman primers (Thermo Fisher Scientific, Rockford, IL) normalizing the
genes to housekeeping gene GAPDH and analyzing the response of the following markers:
alkaline phosphatase, osteocalcin, osteopontin, collagen 1a1, and RUNX-2.
The same analysis was performed for the cells encapsulated in rat tail Collagen Type I
(BD Biosciences, Franklin Lakes, NJ) hydrogels (1, 2, and 3 mg/mL). The cells were added
at a density of 250,000 per 3 mL per 6-well plate at the last step of the collagen solution
preparation on ice, mixed thoroughly, and immediately placed in a 37°C incubator where they
were allowed to gelate. After gelation, 2 mL of media was placed on top of each hydrogel
construct and replaced every 48 hours. To verify viability, MC3T3 cells were immunostained
with a live/dead assay (Invitrogen, Carlsbad, CA) and imaged with a LSM 510
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META/ConfoCor 2 system (Zeiss, Oberkochen, Germany) before, during, and after LIPUS
treatment to verify that cells remained viable and alive.
Additionally, to evaluate whether LIPUS impacted cell proliferation in hydrogels,
MC3T3 cells were encapsulated in 3 mL of 1 mg/mL (0.1%) collagen type I hydrogel
concentration in six-well plates in alpha-MEM media supplemented with 10% FBS and 1%
P/S. Cells encapsulated in collagen were maintained in 37°C and 5% CO2 and medium was
changed every two days. Cell cultures were treated each day with the clinical intensity of
LIPUS (30 mW/cm2) for 20 min/day (experimental group) and no LIPUS (control group) over
1, 3, and 7 day time points. At each time point, cells were isolated by digesting the collagen
hydrogel with enzyme collagenase (Thermo Fisher Scientific, Waltham, MA) and centrifuged
to form a cell pellet. The cell pellet was re-suspended in 400 mL of PBS and 2% FBS from
Gibco (Grand Island, NY). Propidium iodide (1 mL/400 mL) was added to each sample
(1uL/400uL for each group) to fluorescently tag the dead cells, and the total number of viable
cell count was measured by magnetic-activated cell sorting (Miltenyl Biotec, Germany). Oneway analysis of variance (ANOVA) statistical analysis was used to determine statistical
significance between each group (p<0.05). Additionally, LIPUS treatment and no treatment
was compared with MC3T3s both on TCP and in the same viscosity hydrogels as listed above
with the confocal microscope; however, an Actin stain (Molecular Probes, Eugene, OR) was
used with a z-stack acquisition and rendering (Zeiss software suite) in the hydrogels to
visualize cell morphology differences between LIPUS and control groups as well as actin
filament alignment and polymerization.
To investigate osteogenic response or expression, the cell-encapsulated hydrogels were
exposed to the clinical intensity of LIPUS (30 mW/cm2) for 1, 3, and 7 days for 20 minutes
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per day (experimental group) and no LIPUS treatment (control group). At each time point,
media was aspirated from each hydrogel and then rinsed with HBSS (Gibco, Grand Island,
NY). Additionally, in order to digest the collagen scaffolds, collagenase (Gibco, Grand Island,
NY) was used according to protocol. Each digested well with cells was placed into a 15 mL
centrifuge tube and spun down. After this point, the qRT-PCR process was the same as with
the TCP protocol above; the cell pellet was resuspended with the first solution of the Qiagen
RNeasy kit (Valencia, CA) and extracted to proceed as described by the protocol. However,
an additional marker of interest was added for qRT-PCR analysis, cyclooxygenase-2 (COX2), officially known as prostaglandin-endoperoxide synthase 2 (PTGS2), which has shown
upregulation in osteoblasts from mechanical stimuli both in vitro307,308 and in vivo.309 This
study was repeated by the same parameters listed above except for the time points. As COX2 is expressed very quickly after mechanical stimulus, the experimental group was
administered ultrasound for 20 minutes and samples were collected immediately after
treatment and 30 minutes after. Additionally, based on results, varying LIPUS intensities were
applied to the MC3T3 cells: particularly 30, 150 and 30 mW/cm 2. We hypothesized that the
acoustic radiation force from ultrasound treatment would provide a similar mechanical
stimulus hence resulting in a positive correlation between COX-2 expression and LIPUS
treatment and also intensity.
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4.3. Results

The in vitro results with MC3T3-E1 cells from our studies are discussed in this section.
Figure 39 shows a light microscopy image of MC3T3-E1 cells’ growth and morphology in a
three-dimensional environment, a 0.1% collagen hydrogel, after seven days (figure 41A)
compared to a phase-contrast image of MC3T3-E1 cells grown on TCP (figure 41B). The cells
had a different morphology compared to ones grown on TCP that acquired a more quilted and
patterned look. In three-space, cells were able to migrate and grow in any direction by
extending processes from the center of the cell body.
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A

50 µm

B

Figure 39. Light microscopy image of MC3T3 cells encapsulated in a 0.1% collagen
hydrogel (3-dimensional matrix) and cultured for 7 days (A) [mag]. Phase-contrast
microscopic appearance of MC3T3-E1 cells in day-2 cultures (2-dimensional substrate,
TCP), mag = 250X (B). Morphological differences can be seen between both growth
environments.
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Figure 40. Confocal microscopy image of a LIVE/Dead assay indicating abundant MC3T3
viability of encapsulated cells in a 0.1% collagen hydrogel within 24 hours of culture.
Viable cells appear green while dead cells appear red (circled in white) (mag = 10X).

Figure 42 shows a confocal microscopy image of MC3T3 cells treated with the
live/dead assay. Live cells are shown in green after 24 hours of culture in a 0.1% collagen
hydrogel, while the dead cells are shown in red. It is clear from the image that there was
abundant cell viability when cells were cultured for 24 hours given that the image shows mostly
green (live) cells and a very limited number of red (dead) cells which are circled in white for
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ease of visibility. Cells were able to proliferate, migrate, and remain viable within their growth
environment of collage type I hydrogel.

Figure 41. Proliferation study of MC3T3 cells encapsulated within a 0.1% collagen
hydrogel with (experimental) and without (control) ultrasound treatment

The MACs system with flow cytometry demonstrated no statistically significant
difference in viable cell count in terms of LIPUS treated versus untreated cells in 0.1% collagen
hydrogels (figure 43) as well as LIPUS treated versus untreated cells on TCP (figure 44).
Viable cell count increased in both LIPUS treated and untreated groups over three days;
however, at the 7 day time point viable cell count dropped off by about 30%. From numerous
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studies and trials, the collagen hydrogels seemed to have an upper limit on workability at
around one week where the hydrogels would begin to detach from the cell culture dish, or
degrade, or shrink. This resulted in difficulty in consistency of experimental parameters for
desired studies beyond a one week timeframe. Therefore, for feasibility reasons, we did not
extend our collagen hydrogel studies beyond 7 days.

Figure 42. Proliferation study of MC3T3 cells cultured on TCP with (experimental)
and without (control) ultrasound treatment.
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Figure 43.

Gene expression of MC3T3-E1 cells cultured on TCP of five different

osteogenic markers with (experimental) and without (control) ultrasound treatment over
3, 7, 14, and 21 days.

A 3, 7, 14, and 21 day study of LIPUS treated and untreated MC3T3 cells on TCP
showed a positive correlation between LIPUS treatment and alkaline phosphatase (ALP) and
collagen 1a1 (COL1a1) expression (figure 43). ALP and COL1A1 expressions both peaked
in the untreated groups at day 7 and subsequently decreased over 14 and 21 days. The groups
treated with LIPUS gradually and sustainably increased from the first measured expression
level at day 3 all the way until day 21.
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1 mg/mL

2 mg/mL

3 mg/mL

Figure 44. Proliferation study of MC3T3 cells encapsulated within at 0.1% collagen
hydrogel with and without ultrasound treatment

In a 1, 3, and 7 day study in 0.1, 0.2 and 0.3% collagen hydrogels with 20 minute daily
treatments of LIPUS, the 0.1% collagen hydrogels treated with LIPUS demonstrated a
statisticaly significant (P < 0.05) upregulation in alkaline phosphatase (ALP) and osteocalcin
(OCN) expression, two markers of osteogenic differentiation, at the 7 day time point (figure
46).

As collagen concentration increased, as in the 0.2% collagen hydrogel study, the

expression of ALP and OCN was not statistically greater in the LIPUS treated group in
comparison to the untreated group during any of the 1, 3, and 7 day time points. The 0.3%
collagen hydrogel study showed the most irregularity and variability in data with no groups
expressing statistically different expression levels; however, at the 7 day time point, expression
levels of ALP was similar between LIPUS treated and untreated groups, and OCN expression
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level was decreased for the LIPUS treated group in comparison to the untreated group, possibly
suggeseting a reversal of the trend seen in the 0.1% hydrogels.

Figure 45. COX-2 expression levels after 30 minutes of MC3T3-E1 cells cultured on TCP
and encapsulated in 0.3% collagen hydrogels both treated (experimental) and untreated
(control) with LIPUS.

COX-2, an indicator of mechanical stress, showed upregulation in MC3T3-E1s in
groups treated with LIPUS in 0.3% collagen hydrogels in comparison to the same groups left
untreated on TCP (figure 45). Additionally, within the collagen hydrogels, both LIPUS groups
(30 and 150 mW/cm 2) showed a statistically significant (P < 0.5) upregulation in comparison
to the control hydrogel. Even the control hydrogel seemed to have an increase in expression
simply due to cellular culture in the hydrogel in comparison to the TCP control; however, the
increase was not statistically significant with a sample size of n=3.
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Figure 46. Confocal image of f-actin immunostained MC3T3-E1 cells cultured on TCP and
in a 0.3% collagen hydrogel with and without ultrasound treatment.

Confocal images of MC3T3 cells immunostained with f-actin show filaments are highly
polymerized and organized with the cells seeded on TCP both without (A) and with (B)
acoustic radiation force (figure 48). With the cells cultured in the 0.3% collagen hydrogels,
actin is disorganized and lacks actin fiber alignment both without (C) and with (D) acoustic
radiation force.
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4.4. Discussion

Results showed positive feasibility of growing or encapsulating pre-osteoblasts
(MC3T3-E1 cells) in collagen hydrogels. Further, the osteogenic marker expression showed
statistically significant differences between MC3T3 cells treated with acoustic radiation force
compared to cells that did not receive treatment in various markers depending on the substrate
(TCP or collagen hydrogel) that they were grown on. Acoustic radiation force appears to be a
driving factor in the response of MC3T3s not only with osteogenic markers alkaline
phosphatase and osteocalcin, but also the mechanosensory marker COX-2. While researchers
remain unclear on the exact bioeffects of LIPUS in terms of fracture healing, our hypothesis
linking acoustic radiation force to mechanotransduction as a driving force seems feasible
considering the upregulation of COX-2 expression from LIPUS treatment.
Fluid shear stress has been shown to promote COX-2 and prostaglandin E2 (PGE-2)
release in MC3T3-E1 cells by the formation of focal adhesions on fibronectin. 310 PGE-2 is
downstream of COX-2 and is a potent activator of the Wnt signaling pathway. Both PGE-2
and COX-2 are considered principle mediators of inflammation in diseases such as rheumatoid
arthritis and osteoarthritis.

Nonsteroidal anti-inflammatory medications (NSAIDs) and

selective cyclooxygenase-2 (COX-2) inhibitors such as Celebrex™ (celecoxib) are commonly
clinically prescribed in orthopedics to reduce PGE-2 production to diminish the inflammation
seen in these diseases, but present risks from continued use that may include both
gastrointestinal bleeding and prothrombotic tendencies.311 Additionally, PGE-2 has been
implicated in regulating the developmental specification and regeneration of hematopoietic
stem cells through cAMP/PKA activity. 312 While over expression of inflammatory signals can
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be clinically bothersome, appropriate expression is certain instances can also be beneficial
such as in mechanotransduction in bone.

Considering the current knowledge of the

mechanosensory expression of COX-2 and our demonstration of acoustic radiation force in
addition to the acoustic streaming phenomenon demonstrated during our dye experiment in a
fish tank, we suggest that the in vitro upregulation of COX-2 in response to ultrasound
treatment comes from either the stimulus of acoustic radiation force, acoustic streaming, or
perhaps a combination of both.
As acoustic radiation force did not show any negative signs of treatment in terms of
proliferation and cell viability on TCP and in collagen hydrogels, we were successfully able
to proceed with further studies investigating the effects of mechanical stimulus in vitro. Actin
is the most abundant protein in most eukaryotic cells. Actin filaments (F-actin) are linear
polymers of globular actin (G-actin) subunits and exist as microfilaments in the cytoskeleton.
Both F-actin and G-actin are essential for important cellular functions such as the mobility and
contraction of cells during cell division. 313 Effects of substrate stiffness on cell morphology,
cytoskeletal structure, and adhesion have been well documented in literature. 314 F-actin
polymerization is affected by mechanical stimuli and has been studied in mechanobiology
pathways315 and is of interest to its translation in bone mechanotransduction. MC3T3-E1 cells
immunostained for f-actin showed that softer substrates such as the collagen hydrogel, did not
possess highly organized or polymerized F-actin independent of whether receiving LIPUS
treatment. Additionally, the MC3T3-E1 cells grown on TCP, a hard surface, showed a high
level of F-actin polymerization both with and without LIPUS treatment. As F-actin plays a
significant role in cell attachment and mobility, it is likely that the softer substrate collagen
hydrogels opposed to the rigid substrate TCP did not provide a sufficient amount of mechanical
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stability, leading to less F-actin production and polymerization which has been a similar them
with other matrices of lower mechanical stability. 316,317 While lower F-actin polymerization
may indicate decreased cellular attachment and migration in the collagen hydrogels studied,
the in vitro collagen hydrogel model may not necessarily translate to in vivo results. TCP has
been widely used for in vitro cell studies as it has been optimized for cellular attachment. As
such, drawing early conclusions by comparing the results on the two substrates may be lead
premature and incorrect assumptions. Additionally, in this in vitro collagen hydrogel system,
the MC3T3-E1 pre-osteoblast cells were analyzed in an environment early in their maturation
process, where native bone tissue, as a naturally occurring composite material, proximally
exhibits the rigidity of the calcium phosphate matrix. With this in mind, in vivo response of
F-actin polymerization under the mechanical stimulus of acoustic radiation force through
LIPUS may be significantly different in comparison to results seen in vitro, particularly with
other local environmental nutrient exchange and biochemical signaling.
The fabrication of collagen hydrogels and the length of time for an appropriate level of
workability depends on the collagen concentration, but in general most collagen hydrogels
start degrading at around one week. Future studies as well as possible use in a clinical setting
will require a more consistent methodology and confidence in a more prolonged collagen
hydrogel matrix sustainability to ensure encapsulated cells stay localized within the hydrogel
which is desired for successful defect repair. Furthermore, we have successfully developed a
methodology to encapsulate MC3T3-E1 pre-osteoblasts in collagen hydrogels of a desired
mechanical stiffness, or storage modulus, based on the collagen concentration used during
scaffold fabrication. Importantly, the developed cell encapsulation protocol will likely support
other cells and be a feasible solution to inject patient-specific cells such as mesenchymal stem
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cells into the defect site where they will likely remain localized and be held in place long
enough to establish their own extracellular matrix. A common hurdle to overcome with cell
and drug-based therapies for tissue engineering applications is the successful delivery of the
cells or drug(s) in the immediate location of the defect, prevention of the cells or drug(s)
leaving the vicinity, and their sustainability. Since the collagen hydrogel gelates once it is
neutralized with a base and heated to 37°C, it is a possibly feasible delivery solution to
localize and maintain the cells in the defect.

Some investigation of length of time for

degradation to occur in vivo would be useful considering the time in a culture dish with little
disturbance or fluid exchange still degrades the hydrogel after about only a week. It is likely
that degradation would occur much quicker in vivo which could be a potential pitfall.
Ultimately what is important is if the collagen hydrogel has enough time to deliver the cells to
the defect because the primary use of the hydrogels are delivery vehicles for cells and
potentially growth factors as well. Early termination of the hydrogels functionality to deliver
cells and not be harmful to local cells and tissue may need further investigation. Additionally,
in terms of LIPUS treatment, clinical use could go on for 4-8 weeks until the defect is fully
healed hence is the second reason why the hydrogels need to hold their integrity – so that they
can serve as a deformable and loadable matrix.
Importantly, with acoustic radiation force, we can remotely and non-invasively load the
cells to further enhance and accelerate bone healing beyond the use of LIPUS alone and to
potentially avoid the need for invasive surgical intervention where complications and problems
may occur. Additionally, with high medical costs and the patient’s decision to undergo surgery
where there will be significant post-operative pain as well as a lengthy healing time, a more
feasible and effective option is to load the patient’s own mesenchymal stem cells using acoustic
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radiation force by injecting the solution of the patient’s cells and collagen hydrogel into the
defect site to form the cell-encapsulated collagen hydrogel scaffold. With the cells held in
place and feeling the physical load of daily applied acoustic radiation force treatments, the
cells will likely differentiate down the bone lineage and provide new and remodeled bone
formation. Before clinical implementation of this treatment can be pursued, other in vivo
studies may provide insight into how loaded cells respond to acoustic radiation force which
leads us to the final specific aim and study with a mouse calvarial defect model.
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5. SPECIFIC AIM III: ANALYSIS OF ULTRASOUND TREATMENT IN VIVO:
MOUSE CALVARIAL DEFECT WITH COLLAGEN HYDROGELS

5.1. Introduction

Non-invasive, transcutaneous LIPUS therapy has shown clinical efficacy in bone
healing for over two decades. Studies have shown that LIPUS therapy is capable of reducing
fracture healing time by 38% in addition to healing non-union defects at an 85% success rate.269
As mentioned earlier, commercially available clinical units for orthopedics do not deviate from
a particular set of parameters likely in part due to the fact that the underlying biological
mechanism responsible for the wearable device’s efficacy still remains largely unknown which
is a major theme of this thesis. If a particular clinical treatment has proven efficacy and its
mechanism of action remains unknown, then altering certain parameters will result in too many
variables being changed and the chance of optimization will diminish.

Additionally, a

consistent method for measuring clinical efficacy is required in order to compare studies with
various parameter differences in order for LIPUS optimization or discovery of mechanism(s)
of action. Unfortunately, in the hundreds of LIPUS studies published, the measurement of
clinical efficacy ranges from radiographical healing to various directly assessed functional end
points such as time to return to regular daily activities or full weight bearing.318
While certain parameters may be limited to any degree of adjustment in the clinical
setting due to regulatory and intellectual property factors such as the selection of a 30 mw/cm 2
spatial intensity by the FDA’s approval in 1994 for the use of LIPUS in the treatment of fresh
fractures and subsequent approval in 2000 for treatment of non-union defects, a parameter is
not limited to change for in vitro investigations as well as in pre-clinical in vivo studies. Much
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of the work of this thesis involved the analysis of LIPUS therapy to cells or their scaffolds or
both by the use of a highly tunable ultrasound system developed and characterized in specific
aim I. The final objective of this work is two-fold which will soon become apparent as
indicated in the final specific aim of this thesis: first, the optimization of LIPUS therapy for
bone regeneration, and second, the evaluation of LIPUS therapy by the physical force
manifested by acoustic radiation force by hypothesizing that a physical force loading cells and
their extracellular matrix is directly linked to the mechanism of action resulting in clinical
efficacy. In terms of optimizing the use of LIPUS therapy, a hydrogel system such as the
collagen hydrogel scaffold characterized earlier can serve as a carrier and deliver patientspecific cells to a particular defect and subsequently hold the cells in place so that LIPUS
treatment can result in acoustic radiation force physically loading and deforming the cell hydrogel constructs. As discussed earlier, bone responds positively to physical force via
Wolff’s law; however, during a typical fracture recovery, the physician immobilizes the
fracture to avoid further damage or complications to the defect and surrounding tissues. In
terms of bone regeneration, this concept sounds somewhat counter-intuitive. Therefore, if an
immobilized defect site could somehow be physically loaded in a minimal way to not cause
further damage or increased pain, the defect site may in theory respond positively to some
physical forces.
A perfect way to achieve this concept is to use the previously characterized cellencapsulated hydrogels to deliver patient-specific cells to the defect site through a syringe.
Gelation of the collagen hydrogel would occur at body temperature which would localize and
maintain the cells at the defect hopefully long enough for a series of daily LIPUS treatments
to physically load and deform the cells and hydrogels to accelerate fracture healing. With the
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method described, we could satisfy our goals to optimize or improve LIPUS therapy efficacy
compared to the current clinical therapy in addition to using acoustic radiation force as a
modality to physically load cell-hydrogel constructs. If a significant improvement occurs
compared to control groups, with the data taken into consideration in the previous specific
aims, combined results may ultimately provide evidence that the underlying mechanism of
LIPUS efficacy in bone regeneration is indeed related to acoustic radiation force.
For our in vivo investigation, we hypothesized that results would reveal accelerated
healing in defects filled with donor cell-loaded hydrogels of optimal viscosity to best transfer
remotely applied acoustic radiation force to encapsulated cells. This would provide important
proof-of-concept data to expand the exploration of loading bony defects with malleable
constructs capable of being transcutaneously deflected to impart mechanical loading on both
resident and neighboring cells. An animal model was developed and verified for its utility for
such an application, hydrogel incorporation for bone repair. As previously discussed, we
tested whether or not a physical force can be transmitted and measured on the other side of
skin tissue it is coupled with in case the signal was not strong enough and would attenuate
through a particular tissue. By evaluating the transmission of mechanical forces through a rat
skin flap, we detected only minor attenuation of the impulse and therefore are confident that
mechanical deflection of the implanted hydrogel would take place form the applied acoustic
radiation force. As this study was the first in vivo ultrasound experiment in our lab, it was
performed as a pilot study with a limited number of groups, but was performed to help lay the
groundwork for future investigations.
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5.2. Materials and Methods

A mouse calvarial defect model was chosen for performing an in vivo study to
ultimately help tie concepts together as mentioned above by investigating in vivo bone healing
response. Our in vivo analysis showed the efficacy of the combined treatment of LIPUS with
an injectable BMSC-encapsulated type I collagen hydrogel over a healing time of 2 or 4 weeks
in a mouse calvarial defect model. All procedures were done in accordance with approved

Figure 47. Picture of the mouse calvarial defect hydrogel implantation wound closing (left)
and post-surgery (right).

Institutional Animal Care and Use Committee guidelines.

The groups consisted of the

hydrogels with encapsulated donor cells without LIPUS treatment (control) and hydrogels with
cells and with LIPUS treatment (experimental). Briefly, samples were evaluated using x-ray
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imaging, and histological analysis was performed on samples to evaluate the extent of donor
cell survival, new bone formation, mineralization, and remodeling.

Figure 48. Pictures of cranial tissue excision post-sacrifice (left) and excised cranial tissue
sample for processing (right).

BMSCs in recipient tissues were isolated from reporter mice. The skin at the surgical
site was cleanly shaved and disinfected and a sagittal skin incision was made from the occipital
to the frontal bone. The skin flap was then bluntly dissected and elevated. To minimize the
regeneration potential from host osteoprogenitor cells residing in the periosteum we carefully
dissected and removed the periosteum covering the entire defect. One 5 mm diameter full
thickness defect was created on the left parietal bone with a 5-mm trephine bur under saline
irrigation while preserving the underlying dura mater (figure 47). The space was filled with
cell-loaded hydrogels (500,000 cells per gel) of the viscosity determined most effective in
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Specific Aim 1, 3 mg/mL, and the skin flap sutured closed. Hydrogels without cells served as
controls. Hydrogels were made according to protocol as previously discussed, except for the
gelation process, where 200 µL of hydrogel was formed within a 1 mL syringe at 37°C for
gelation into a suitable diameter (5 mm) and height for the defect site.

Figure 49. In vivo setup showing LIPUS application while mouse is under anesthesia with
the nose cone and stereotaxic device.

Defects receiving acoustic radiation force had ultrasound gel coupled between the
transducer and skin over the defect site were loaded for 20 minutes per day five of every seven
days (five days on, two days off) throughout healing for 2 or 4 weeks. LIPUS was administered
using 150 mW/cm2 spatial intensity and the transducer was calibrated according to the protocol
for ultrasound characterization as discussed in Specific Aim I. The mice were positioned on a
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stereotaxic device (Stoelting) for LIPUS treatment over the defect site while under anesthesia
(figure 48). The ultrasound transducer was positioned and held by a clamp with an adjustable
base. Groups were given an IP injection of alizarin red complexone one day prior to sacrifice
to identify actively mineralizing surfaces. After sacrifice, calvarial tissue was excised and
processed (figure 49). Histology analysis was performed according to protocols for DIC,
alkaline phosphatase, DAPI, GFP, alizarin red complexone, and TRAP staining.
Representative samples were evaluated for the presence of encapsulated BMSC cells (GFP+
cells) to study the extent of donor cell survival and inflammatory cells. Defect loading with
acoustic radiation force was compared to no loading, while presence of cells was compared to
no cells. The osteogenic efficacy of loading and cell encapsulation was assessed based on the
increase in mineralized bone volume. Microscopic evaluation of interface tissue morphometry
provided high-resolution quantization of peripheral integration, discriminating whether or not
the repair tissue has incorporated via a relatively seamless continuation of morphometry across
the interface versus a remaining boundary requiring further remodeling.
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5.3. Results

Figure 50. Calvarial defect samples 2 weeks post-surgery. Pictures of samples were
taken (left) and samples were imaged via x-rays (right). Sample on the top did not receive
LIPUS treatment while the sample on the bottom received LIPUS treatment.
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Figure 51. Calvarial defect samples 4 weeks post-surgery. Pictures of samples were
taken (left) and samples were imaged via x-rays (right). Sample on the top did not
receive LIPUS treatment while the sample on the bottom received LIPUS treatment.
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LIPUS

DIC

NO LIPUS

Figure 52. DIC histology imaging of bone healing after 4 weeks showing effects of LIPUS
treatment (top) and without LIPUS treatment (bottom).
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LIPUS

ALKALINE PHOSPHATASE

NO LIPUS

Figure 53. Alkaline phosphatase histology imaging of bone healing after 4 weeks showing
effects of LIPUS treatment (top) and without LIPUS treatment (bottom).
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LIPUS

DAPI

NO LIPUS

Figure 54. DAPI histology imaging of bone healing after 4 weeks showing effects of LIPUS
treatment (top) and without LIPUS treatment (bottom).
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LIPUS

GFP (DONOR CELLS)

NO LIPUS

Figure 55. GFP histology imaging of bone healing after 4 weeks showing effects of LIPUS
treatment (top) and without LIPUS treatment (bottom).
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LIPUS

ALIZARIN COMPLEXONE (NEW BONE)

NO LIPUS

Figure 56. Alizarin complexone histology imaging of bone healing after 4 weeks showing
effects of LIPUS treatment (top) and without LIPUS treatment (bottom).
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LIPUS

TRAP (OSTEOCLAST ACTIVITY)

NO LIPUS

Figure 57. TRAP histology imaging of bone healing after 4 weeks showing effects of LIPUS
treatment (top) and without LIPUS treatment (bottom).

New bone formation was most evident in 4 week time points with LIPUS treated groups
expressing greater evidence of bone healing compared to groups that did not received LIPUS
treatment. As expected, less bone healing was seen at the 2 week time points; however, some
LIPUS groups did indicate enhanced healing with LIPUS compared to the group left untreated.
Two week samples are shown with photographic imaging and x-ray imaging (figure 50). The
x-ray imaging indicated enhanced mineralization in the center and some of the edges of the
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defect where LIPUS treatment was applied, while the group without treatment showed minimal
and more randomized mineralization and less mineralization at the edges of the defect.
New bone formation was more evident in the four week time points (figures 51 -57).
Mineralization as shown by x-ray imaging was enhanced in the defect receiving LIPUS in
comparison to the defect left untreated (figure 51). The defect receiving treatment s howed
well-disbursed mineralization throughout the defect site including at the edges of the defect;
however, it was evident that mineralization and total healing was not complete at this time.
Additionally, the photographic image of the calvarial defect tissue receiving LIPUS treatment
showed enhanced tissue growth compared to the defect that did not receive treatment.
Furthermore, x-ray imaging of the defect at 4 weeks without LIPUS treatment showed
significantly less mineralization throughout the defect, particularly at the edges of the defect.
For comprehensiveness, further analysis for 4 week bone healing evidence was
provided by histological analysis of the calvarial defect and host bone healing and integration
by analyzing calvarial tissue cross-sections. DIC imaging showed enhanced healing clearly
with high contrast in the LIPUS treated group in comparison to the group without treatment
(figure 52). The tissue evidenced nearly complete continuity with a strong signal across the
defect site and into the adjacent host bone while the defect site without LIPUS treatment
evidence clear discontinuity and a large gap in bone tissue nearly spanning the entire site of
the defect indicating minimal tissue regeneration occurred. Alkaline phosphatase staining, an
indicator of bone mineralization, provided significant evidence of substantial bone healing in
the 4 week defect site receiving LIPUS treatment shown by high signal expression indicating
higher contents of mineralization and continuity across most of the defect site with appropriate
integration into the local host bone tissue (figure 53). Signal for alkaline phosphatase was
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evidenced on the exterior and interior of the defect bone formation, indicating high mineral
deposition in the formation of cortical bone. The defect site that did not receive LIPUS
treatment expressed significantly less alkaline phosphatase expression through lack of
continuity across the defect site and lack of integration into the host bone.
DAPI histological expression, a stain for nuclei, was of significance as the imaging
helped assess the level of active cells in the process of bone healing in comparison to alkaline
phosphatase activity that expresses an extracellular deposit, which may remain in the local
tissues independent of current cell viability. DAPI expressed high signal at 4 weeks for the
defect site treated with LIPUS in comparison to the defect that did not receive treatment (figure
54). Additionally, again the defect that received LIPUS treatment expressed tissue growth and
continuity across the defect site and into the host tissue. Greater signal was seen on the
interiors and peripheries of the implant, indicating cellular activity and proliferation. While
DAPI expression remained continuous in the defect site that did not receive LIPUS treatment,
the signal did not evidence a formation of a periphery and interior tissue and cell formation.
GFP, a fluorescent stain for indicating the hydrogel implant’s encapsulated donor cell
survival, expressed less signal than the other stains after 4 weeks for both LIPUS treated and
untreated groups (figure 55). However, signal was stronger in the defect receiving LIPUS
treatment, although the expression was not continuous across the defect site and into the host
tissue. Furthermore, the expression of GFP in the defect without LIPUS treated as significantly
less and there was virtually no signal in the implant/defect site, while some signal was seen at
the edges of the defect site where some donor cells appeared to survive.
Alizarin red complexone is an indicator of new bone formation and was expressed by
evidence of slightly greater signal in the defect that received LIPUS treatment in comparison
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to the defect without LIPUS treatment (figure 56). However, signal expressi on was not very
high in either group. Slightly more continuity was seen in the LIPUS treated defect along with
a thicker calvarial bone formation evidenced by a thicker band of signal. While the defect that
did not receive treatment expressed a mostly continuous signal indicating bone formation
across the majority of the implant, the thickness of bone formation was much thinner in
comparison to the defect treated with LIPUS as the band of signal was thinner and less intense.
TRAP staining indicated the level of osteoclast activity in the defect bone healing
process. The defect that received LIPUS expressed greater signal after 4 weeks than the defect
that did not receive LIPUS (figure 57). However, both groups expressed a discontinuous signal
indicating lack of continuity and formation or migration of osteoclasts across or throughout
the defect sites.

The defect that received LIPUS did express greater signal expression

throughout the defect and at the defect-host tissue edges. The defect without LIPUS treatment
expressed great discontinuity as there was nearly no signal except for that the host bone
interfaces.
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5.4. Discussion
Our in vivo investigation was conducted to provide important proof-of-concept data to
expand the exploration of loading bony defects with malleable constructs capable of being
transcutaneously deflected to impart mechanical loading on both resident and neighboring
cells. We previously hypothesized that results would reveal accelerated healing in defects
filled with donor cell-loaded hydrogels of optimal viscosity to best transfer remotely applied
acoustic radiation force to encapsulated cells. Results at 4 weeks were more conclusive of
bone regeneration and healing than the data demonstrated at 4 weeks; however, a 2 week period
of bone healing is still premature in terms of the length of a typical fracture healing process,
and there was still evidence of early bone healing in some groups.
As discussed previously, the mechanisms of action of LIPUS efficacy for fracture
healing remain unknown; however, the data we presented may indicate the possibility between
the mechanical stimulus of LIPUS being linked to mechanotransduction pathways. Wit h the
in vitro studies, alkaline phosphatase and osteocalcin expression was upregulated after 7 days
of LIPUS treatment. Additionally, the marker indicative of mechanical stress, COX -2, was
upregulated in association with acoustic radiation forces. Tying these concepts together along
with other work through the research community, there is a likelihood that acoustic radiation
force through LIPUS therapy for fracture healing may be effective in part through mechanical
stimulation of cells at the fracture site resulting in mechanotransduction and enhanced bone
regeneration in comparison to no treatment.
Significantly, our work demonstrated a few key findings for the use of implantable
scaffolds as delivery vehicles for cell therapies in bony defects. Although evidence of bone
healing at 2 weeks from LIPUS treatment did not greatly outweigh imaging results from the
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groups without treatment, x-ray imaging of the defect treated with LIPUS did indicate greater
signal at the edges of the defect where the defect without LIPUS treatment showed minimal to
none, importantly indicating that LIPUS treatment resulted in early mineralization formation
and seemingly initiated bone formation (figure 50). Furthermore at 4 weeks, the photographic
images of the calvarial defect sites indicated a more continuous and consistent coloring in the
regenerated tissue in the defect site in the group treated with LIPUS (figure 51). Intuitively,
this more uniform consistency translated to significantly more mineralization in the LIPU S
treated defect as evidenced by the signal in the x-ray imaging (figure 51) and translated to
increased signal in the images stained for alkaline phosphatase, another indicator of
mineralization (figure 53).
Investigation of cell activity and survival were important as one of our main objectives
in addition to the remote mechanical stimulus of local tissue was the effective delivery and
survival of cells to the defect through hydrogel implantation. Significantly, cell delivery and
delivery and survival appeared successful as GFP imaging provided evidence of signal
somewhat discontinuously across the defect site in the defects treated with LIPUS, but
nevertheless, a positive presence of the encapsulated and implanted GFP-donor cells,
indicating that they were successfully delivered and remained viable after 4 weeks (figure 54).
While the signal for GFP in defects left untreated was significantly less and also discontinuous,
some GFP-donor cells did still survive over the 4 week period independent of LIPUS treatment,
expressing the utility of the hydrogel delivery system alone. On the other hand, the use of
LIPUS treatment did significantly increase GFP-donor cell survival and viability compared to
defects not receiving treatment, indicating that LIPUS directly played a role in cell survival,
possibly through cellular nutrient maintenance and exchange. One theory behind LIPUS
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efficacy suggests that LIPUS induces greater blood flow at the defect site and thus promotes
better in vivo healing.319 It is possible that the hydrogel scaffolds in the defects without LIPUS
treatment were not able to exchange fluids as well for chemical and growth factor t ransport,
receive oxygen, or discard toxins from cellular waste. Reasons for lack of fluid exchange
could be lack of initiation of angiogenesis and vascularization or lack of integration of the
hydrogel into host tissues at physical, chemical, and/or biological levels.
Further evidence of cell viability was expressed by DAPI imaging which provided
conclusive evidence to greater cell presence by staining for cell nuclei in LIPUS treated defects
compared to those left untreated (figure 55). These results suggest the LIPUS is playing a role
in the regeneration of bone tissue and the proliferation of cells as significantly more are present
across the defect site and on its edges both in continuity and in a two-level layer, where a
strong signal was present on the periphery and interior of the scaffold. The defect left untreated
importantly still expressed the presence of cells indicating the utility of our hydrogel system
alone for the successfully delivery of cells to bony defect sites. However, the defect l eft
untreated with LIPUS indicated significantly less signal and also a different arrangement and
presence of stained nuclei. While signal was expressed in continuity across the defect site and
at its edges, there was not an evidence of a two-level layer of bone tissue indicative of cortical
bone formation for calvaria as indicated in the defect treated with LIPUS. This indicates that
likely less tissue was regenerated in terms of calvarial thickness, which may lead to the
conclusion that either LIPUS enhanced and/or accelerated bone regeneration in conjunction
with the hydrogel system, or that the hydrogel system without LIPUS treatment would not be
capable of fully regenerating tissue on its own.
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Histology staining for alizarin complexone indicative of new bone formation expressed
a pattern similar to the DAPI staining (figure 56). The defect treated with LIPUS showed new
bone formation after four weeks in continuity across the defect and its edges on both its
periphery and interior surfaces. The interior of the tissue showed less bone formation with
more inconsistent signal in various areas. The defect without LIPUS treatment also showed
continuity in new bone formation across the defect area and its edges, however there was not
a defined periphery and interior surface as the generated tissue exhibited reduced thickness in
comparison to the defect treated with LIPUS. These results indicate an enhanced level of
healing with combing LIPUS treatment as a remote mechanical stimulus for bony defect
loading with an encapsulated cell hydrogel system. As this study was performed in smaller
sample sizes, a more comprehensive study is warranted for further investigation.
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6. FUTURE DIRECTIONS
Fracture repair continues to be a widely-researched field in medicine. Improved clinical
strategies are continually investigated to address current treatment limitations. Researchers
explore the cellular response to injury, cell fate at the fracture site, and signaling pathways and
mechanisms involved including the role of growth factors and mechanotransduction in fracture
repair.269 The clinical need for fracture repair treatment methods is warranted as there are between
five and six million fractures annually in the United States.320 We have evaluated ultrasound as a
means of producing a transdermal physical force that could stimulate osteoblasts encapsulated
within collagen hydrogels and delivered to bony defects. As we showed that ultrasound does
indeed produce a measurable physical force and when applied to hydrogels causes their
deformation, the possibility to heal bony defects by controlling substrate stiffness and deformation
by applied physical load may be a potential non-invasive therapy with increased efficacy and
affordability. Cell therapy for bone repair has already been used clinically in the form of
autogenous bone marrow aspirate that is collected and re-injected into a bony defect.321

As the

theme of regenerative engineering is translating into clinical treatments, the use of patient-specific
cells and tissue healing potential not only in orthopedics but across all clinical specialties is
emerging compared to more traditional approaches in medicine commonly leading to limitations
of only the treatment of symptoms. As delivery vehicles in biomaterials are being optimized in
biomedical research and translated to clinical therapies, our work here using patient-specific
encapsulated cells within hydrogel matrices as a localized, injectable treatment for bony defects
provides a likely viable option for enhanced bone regeneration applications.
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